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 Chickens infected with Mycoplasma gallisepticum, the primary etiologic agent of chronic 
respiratory disease (CRD), present with significant respiratory complications.  The host response 
is often immunopathogenic and contributes to increased tracheal thickness due to the chemotaxis 
of leukocytes, cellular damage at the mucosal surface, and the inability to clear the infection.  
The response to M. gallisepticum is complex and the differences that lead to a maladaptive 
versus beneficial response are poorly understood.  To elucidate the extent of the host response to 
virulent and attenuated strains, we conducted next-generation sequencing on samples taken 
directly from the host’s tracheal mucosa after infection with either virulent Rlow, or laboratory 
attenuated vaccine strains Mg 7 or GT5. 
 In the first study, transcriptional analysis of the host response to virulent Rlow over a 7-
day infection was conducted on samples from days 1, 3, 5 and 7.  Data indicated a rapid, pro-
inflammatory response, identifying numerous genes involved in immune pathways that peaked 3 
days post-infection, and a significant metabolic response observed on days 1 and 3.  Further 
analysis revealed increased expression of host cell receptors that likely heightens their sensitivity 
to damage- and pathogen- associated molecular patterns and results in the production of 
cytokines and chemokines that recruit and activate immune cells. 
  
Jessica A. Beaudet, University of Connecticut, 2017 
In the second study, comparative transcriptomics identified differences between the early 
host response to Rlow and laboratory vaccine strains, Mg 7 and GT5. Infection with these 
attenuated strains resulted in a dampened host response involving significantly fewer immune 
and metabolism-related genes, limited differential expression of host cell receptors, and 
decreased production of cytokines and chemokines.  Future vaccines should aim to target 
immune genes active in Mg 7 and GT5 infection while avoiding those uniquely differential in 
Rlow infection to induce a protective, and durable adaptive response while avoiding immune-
related exacerbation of disease. 
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CHAPTER 1: Literature Review 
 
Section 1:  Overview 
 
 
Introduction 
 
 Mycoplasmas are atypical bacteria belonging to the class of ‘Mollicutes’.  They are one 
of the smallest self-replicating organisms having evolved from gram-positive bacteria with low 
G + C content through degenerative evolution.  As a result, mycoplasmas have uniquely small 
genomes ranging from as low as 580 Kb in Mycoplasma genitalium (1) to 1,380 Kb in M. 
mycoides subsp. mycoides LC with low G + C content (23-40%) (2), and a high mutation rate 
likely due to inadequate proof-reading by DNA polymerase enzymes (3, 4).  Another unique 
characteristic is their unusual use of the traditional stop codon UGA to encode the amino acid 
tryptophan (5, 6).  Having limited genomic content has also reduced their biosynthetic 
capabilities; mycoplasmas lack the pathways necessary to synthesize peptidoglycan cell walls 
and essential molecules including purines and pyrimidines (2).  Therefore, mycoplasmas rely on 
close association with host cells to acquire sterols that maintain their cell membrane integrity and 
essential nutrients such as amino acids, nucleotides, and fatty acids (2).   
While several mycoplasmas are commensal organisms living as part of the host’s natural 
flora, most are obligate parasites exhibiting highly specific host and tissue tropism(7, 8).  
Susceptible host species include humans, animals, reptiles, fish, insects and plants.  Infection 
commonly results in chronic pathology of the respiratory and urogenital tracts, but are also 
known to cause systemic diseases of the eyes, joints, and mammary glands (2).  Very few 
mycoplasmas cause mortality, however, many are associated with significant disease acting as 
primary, secondary or co-infectious agents.  Costs related to the treatment and prevention of 
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mycoplasma infection and subsequent pathology in humans, pets and livestock results in 
significant economic loss worldwide (2, 9, 10). 
 
History and Nomenclature 
 
Cases of pleuropneumonia in cattle have been documented since 1693, but it was not 
until 1765 that Claude Bourgelat made what has been credited as the first clinical description of 
Bovine pleuropneumonia (11).  This was assumed to be a viral disease, though they had not been 
able to successfully pass the organism in broth or solid media, nor had they been able to observe 
it through light microscopy (11).  In 1898, the etiologic agent of Bovine pleuropneumonia was 
identified by Nocard and Roux (12).  They obtained infectious exudate from a cow with 
distention of the interlobular connective tissue due to accumulation of a clear-yellow albuminous 
serous fluid; characteristic of pleuropneumonia.  A semi-permeable nitrocellulose pouch 
containing sterile peptone broth was inoculated with the exudate and surgically placed into the 
peritoneal cavity of a rabbit, along with an uninoculated and heat-inactivated controls.  After 15-
20 days, the broth containing the infectious exudate became opalescent, with no visible changes 
observed in the controls(12). Upon further cultivation of the organism in peptone broth, they 
were able to experimentally inoculate cattle. This resulted in the development of 
pleuropneumonia; deeming this microbe the causative agent.  
 In 1910, Bordet discovered filaments, vibrios, spirochaetes, and globules after culturing 
and staining the pleuropneumonia ‘virus’.  He believed this was due to ‘metamorphosis’ of the 
virus during prolonged incubation, and that these different morphologies occur during 
developmental stages of the organism.  Bordet proposed the new name Asterococcus mycoides 
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because of the radiating filaments that enveloped the organism while in the streptococci form, 
though retrospectively, these observations were likely due to contamination (11, 13).  The ‘virus’ 
was then renamed again by Martzinovski in 1911, when he failed to replicated Bordet’s findings.  
He concluded that the microbe existed primarily as coccobacillus and therefore, proposed the 
name Coccobacillus mycoides (11, 12).  
It was incorrectly characterized as an L-form of bacteria due to its resemblance to 
Streptococci in 1925. when Bridré and Donatien associated the ‘virus’ with polyarthritis, 
mastitis, and agalactia in sheep and goats (11, 14).  Observational differences found after 
filtering and culturing led them to concluded that there was a second microbe belonging to this 
group.  By 1935, this ‘group’ had seven different names largely because of the efforts made to 
explain the passage of these particles through filters that were impermeable to known bacteria.  
Klieneberger then created the term ‘pleruopneumonia-like organisms’ (PPLO) to describe the 
wall-less group of bacteria, though this did not alleviate the confusion surrounding these 
organisms (11, 14). 
In 1944, the ‘virus’ termed Eaton’s agent, now known as Mycoplasma pneumoniae, was 
discovered in humans suffering from atypical pneumonia.  Passage of this ‘virus’ was successful 
in chick embryos, and was detected by the development of pulmonary lesions in hamsters and 
rats, post-inoculation (15).  The agent was incorrectly classified as a virus because it was not 
affected by antibiotics.  It is known today that the antibiotic β-lactam works by disrupting 
thessynthesis of bacterial cell wall components, a process that is absent in mycoplasmas (11).   
A classification system was created by Edward and Freundt in 1956, which consisted of 
the order: Mycoplasmatales (alternative 1) and Mollicutales (alternative 2), family: 
Mycoplasmataceae, and Genus: Mycoplasma (16).  It was not until 1958, that the etiologic agent 
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of bovine pleuropneumonia was officially named Mycoplasma mycoides by the Judicial 
Commission of the International Committee on Bacteriological Nomenclature.  Nearly ten years 
later, the committee agreed that organisms with the ‘absence of a true cell wall and plasticity of 
the outer membrane’ belong to the class ‘Mollicutes’ (11, 17).  Today, classification of species as 
Mollicutes includes 16S rRNA gene sequence analysis, DNA-DNA hybridization tests, directed 
serology and phenotypic data (11).  There are five orders of Mollicutes; the Mycoplasmatales, 
Entomoplasmatales, Acholeplasmatales, Anaeroplasmatales, and Haloplasmatales, which 
belong to the phylum Tenericutes.  This phylum is related to the Firmicutes phylum consisting of 
other bacteria with low G + C content (18).  Ureaplasmas, determined by their ability to 
hydrolyze urea as an energy source, and Mycoplasma comprise the Mycoplasmataceae family.  
There are 117 known species in the Mycoplasma genus, seven in the Ureaplasma genus, as well 
as several within other families of Mollicutes that are considered legitimate species of 
Mycoplasmas (11). 
 
 
 
Section 2: Mycoplasmosis within Species 
 
Mycoplasma of Humans 
 
 Humans may become infected with several different Mycoplasmas including 
Mycoplasma pneumoniae, M. genitalium, M. hominis, M. penetrans, M. fermentens, and M. 
salivarium, and others.  The most studied of these is M. pneumoniae, the pathogen responsible 
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for causing community-acquired interstitial pneumonia, also known as atypical pneumonia or 
‘walking’ pneumonia (19). Clinical manifestations of atypical pneumonia often develop slowly, 
initially presenting with sinus congestion, pharyngitis, and ostitis media. While the lowere 
respiratory tract is eventually affected, it notably lacks lobar conslidation  (15, 19).   M. 
pneumoniae has also been found in association with asthma and Chronic Obstructive Pulmonary 
Disease (COPD) (20, 21), and less commonly, it has been found to lead to extrapulmonary 
conditions of the central nervous system including encephalitis and meningoencephalitis, 
cardiovascular conditions such as pericarditis, as well as conditions of the gastrointestinal 
system, renal system and the skin (22, 23). 
 It has been estimated that Mycoplasma pneumoniae causes up to 40% of community-
acquired pneumonias (CAP).  Active M. pneumoniae infection can be found in the nose, throat, 
trachea, and sputum, and is transmitted through aerosols (19, 22) with the incubation period 
lasting as long as 3 weeks.  Respiratory illness develops slowly with a dry cough typically being 
the first symptom resulting from tracheobronchitis (19).  While it affects people of all ages, 
infection develops into bronchopneumonia most frequently in school-aged children (22).  
Approximately 50% of asthma patients have evidence of M. pneumoniae infection, during which 
the number of mast cells, bronchial hyperresponsiveness, and Th2 cytokines are found to be 
increased (24). COPD patients are affected by M. pneumoniae in a similar manner; Th2 
cytokines, specifically IL-4, is thought to exacerbate COPD by increasing the presence of 
immune cells and inducing goblet cell hyperplasia.  This subsequently results in mucous gland 
hyperplasia and increases mucus secretion (24, 25).  In addition to immunopathology, M. 
pneumoniae produces a toxin termed the Community-Acquired Resipratory Distress Syndrome 
(CARDS) toxin that has been shown to exacerbate allergic-type inflammation in the airway (26).  
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This ADP-ribosylating and vacuolating cytotoxin (27) acts by binding to, and thereby 
inactivating, human surfactant protein A (SP-A) primarily produced by type II pneumocytes 
(26). 
 Extrapulmonary manifestations of M. pneumoniae occur in as many as 25% of infected 
people.  PCR testing has confirmed the presence of M. pneumoniae in other body sites including 
blood, synovial fluid, cerebrospinal fluid, pericardial fluid, and the skin (22).  However, the 
frequency of its dissemination into tissues is unknown. It is likely that many cases result from 
autoimmune reactions due to sequence similarity of adhesin proteins and glycolipids found in the 
cell membranes of M. pneumoniae with those in mammalian tissues (22, 28, 29).  Encephalitis 
and meningoencephalitis are the most common extrapulmonary complications, with encephalitis 
occurring most frequently in children less than 10 years of age (30).   
 To date, therapeutic and vaccine studies have been unsuccessful.  Early attempts at 
vaccine development included formalin inactivated M. pneumoniae and the creation of 
attenuated strains through repeated passage; however, these approaches  were unable to provide 
adequate protection (31).  Interestingly, a vaccination study in mice reported disease 
exacerbation upon challenge even when vaccinating with a P30 cytadhesin mutant with the 
reduced ability to bind erythrocytes and inability to glide: two functions critical to the infection 
process (32, 33).  Better understanding of the pathogenesis of M. pneumoniae is needed to 
develop effective therapeutics and vaccines. 
 Mycoplasma genitalium is associated with many urogenital infections including 
nongonococcal urethritis, cervicitis, endometritis, and pelvic inflammatory disease (PID), and 
has also been found in association with infertility (34).  HIV patients have been shown to have 
higher rates of infection, though aside from these patients being immunocompromised, the 
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association between these two infections is poorly understood (35).  M. genitalium is very 
difficult to culture as it requires cocultivation in Vero cells and may take months to grow (36). 
Diagnosis can be performed with either PCR or transcription-mediated amplification assays, 
however, there are currently no commercially available, FDA-approved diagnostic tests on the 
market. (37–39).  The difficulties with culturing and lack of standardized detection has 
negatively affected efforts made to understand M. genitalium’s mechanisms of pathogenesis and 
impacts on human health (40).  Coinfection of M. genitalium with Chlamydia. trachomatis or 
Neisseria gonorrhoeae is common (41). Women with M. genitalium infection or coinfection 
present with inconsistent symptoms including pelvic pain, inflammation, and mucopus (42).  
Those suspected to be infected with M. genitalium often receive one of the recommended 
syndromic therapies for nongonococcal urethritis or cervicitis such as doxycycline, though this is 
not very effective.  Azithromycin has been preferred due to high cure rates, however bacterial 
resistance to this treatment has rapidly emerged (39, 43).  
 Another Mycoplasma capable urogenital colonization is M. hominis.  While this organism 
has been found to be present in the absence of disease, it has been associated with bacterial 
vaginosis, infertility, pre-term births, and has been found present in PID (44, 45).  Pro-
inflammatory cytokine and chemokine levels have been found to be increased in amniotic fluid 
when M. hominis infection is associated with pre-term births, and is also thought to play a role in 
subsequent brain damage of the infant (46, 47).  IL-4, a Th2 inducing cytokine, has also been 
found at higher concentrations in amniotic fluids when compared to other infections such as U. 
urealyticum.  Differences in cytokine activation between U. urealyticum and M. hominis may 
suggest the means by which M. hominis is able to evade immune destruction and allow it to 
persist (48).  The M. hominis gene goiC, has recently been found in association with higher 
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bacterial loads and pre-term birth compared to isolated mutant strains lacking this gene, 
suggesting a potential role in virulence (47).  Some studies have found M. hominis in other areas 
of the body including the lungs of transplant patients (49, 50), the skin and soft tissue of an 
immunocompromised pediatric patient (51), however further study is needed.   
 Mycoplasma penetrans is capable of infecting the urogenital and respiratory tracts (44, 
52).  First isolated from the urine of an HIV infected patient, subsequent studies have shown a 
strong association between the incidence and progression of both M. penetrans and HIV 
infections (53).  M. penetrans first adheres to host cells, binds fibronectin and then induces 
cytoskeleton rearrangement through aggregation of tubulin and α-actinin resulting in their 
internalization within host cells (54).  The protein MYPE9110 from M. penetrans has ADP-
ribosyltransferase activity similar to the CARDs toxin found in M. pneumoniae, but has shown 
differences in activity, persistence and host cell targets.  Within the urogenital tract this protein 
acts as a toxin resulting in ammonium chloride-dependent host-cell vacuolization (55).  M. 
penetrans is thought to have a few of different mechanisms to avoid clearance by the host. In 
human serum, M. penetrans has shown to bind IgA, suggesting that it may act to prevent the Fc 
receptor of the IgA from binding to the CD89 receptor on neutrophils; therefore, avoiding host 
recognition and phagocytosis (56).  Lipid associated membrane proteins (LAMPs) of M. 
penetrans has been shown to mediate apoptosis in mouse macrophages through NFκB activation 
(57).  As found in other Mycoplasmas including M. hyorhinis, M. bovis, M. pulmonis, M. 
gallisepticum, M. synoviae, and M. agalactiae, M. penetrans is capable of antigenic variation by 
altering the gene expression of their surface lipoproteins.  Because they are major surface 
antigens, it has been suggested that this contributes to the survival of M. penetrans by avoiding 
recognition by the host immune system (52). 
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 Mycoplasma fermentans was first isolated from the urogenital tract, but has since been 
associated with conditions of the respiratory tract, has also shown to play a role in rheumatoid 
arthritis (RA) (58, 59).  M. fermentans binds plasminogen, fibronectin, heparin and laminin; 
aiding in cell adhesin capabilities (60).  LAMPs from M. fermentans have been shown to induce 
leukopenia and production of granulocyte-macrophage colony-stimulating factor (GM-CSF), 
presumably by macrophages, in the serum of BALB/c mice(61) (61-63).  Expression of 
cytokines IL-6, IL-8, MCP-1, and CXCL1 was increased in human lung fibroblasts exposed to 
M. fermentans, however the reason for the selective upregulation of these cytokines and not 
others remains unknown (59).  Lipoproteins of M. fermentans have been shown to induce ATP 
release and increase membrane permeability of lymphocytes and monocytes resulting in 
apoptosis (62).  The M. fermentans lipid-antigen (GGPL-III) has been shown to be a potential 
virulence factor.  This antigen was detected in nearly 40% of RA patients and resulted in the 
increased production of inflammatory cytokines TNF-α and IL- 6 in mononuclear cells, and was 
also shown to induce the proliferation of synovial fibroblasts (63).  Further study of this 
pathogenic mechanism may assist in the development of immunotherapeutics for RA patients. 
 Mycoplasma salivarium, typically part of the normal oral microbial flora residing in 
dental plaques and gingival sulci, increases in incidence and presence with the progression of 
peridodontal disease, ostitis, pericoronitis and temporomandibular disorders (64). Recently, it has 
also been found intracellularly in epithelial cells of oral leukoplakia (65).  Little is known about 
the pathogenic capabilities of M. salivarium, however studies have suggested its association with 
the progression of periodontal diseases.  Similar to M. penetrans, M. salivarium was found to 
contain proteins capable of binding the Fc fragment of human IgG, suggesting it may prevent the 
binding of IgG with the Fc receptors on neutrophils (66).  M. salivarium has also been shown to 
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play a role in inflammation.  Exposing human gingival fibroblasts resulted in increased 
production of IL-6 and IL-8, two pro-inflammatory cytokines that may contribute to 
inflammatory response seen in periodontal diseases (67).  The oxidant scavenging capacity of M. 
salivarium is another potential self-preservation mechanism by reducing the levels of reactive 
nitrogen and reactive oxygen species that are normally elevated during infection and disease 
(68).    Activation of inflammasomes in dendritic cells and macrophages by M. salivarium was 
recently confirmed. This suggests M. salivarium likely contributes to the increased IL-1β levels, 
a pro-inflammatory cytokine associated with the death of matrix-producing cells in periodontal 
tissues resulting in increased destruction of alveolar bone and periodontal connective tissue (64).  
 Studies of human mycoplasmosis have indicated commonalities between certain species 
related to colonization, pathogenesis and survivability. This has aided in the understanding of 
their association with disease and virulence factors, however, further understanding of their 
pathogenic mechanisms, interaction with, and subsequent host response is needed to develop 
efficacious therapeutics and vaccines. 
 
Mycoplasma of Porcines 
 
 Mycoplasmosis of swineresults in significant economic loss worldwide even though 
mortality rates are low,.  M. hyopneumoniae and M. hyorhinis are the two most commonly 
known Mycoplasmas of swine.  Highly contagious M. hyopneumoniae is the primary agent of 
catarrhal bronchopneumonia and results in poor feed conversion and slow growth.  Infection 
results in epithelial cell hyperplasia and accumulation of mononuclear cells including 
lymphocytes and plasma cells (10).  Known to adhere to ciliated epithelial cells, studies 
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assessing cytadherence of M. hyopneumoniae have found multiple membrane proteins including 
P159 and two repeat regions, R1 and R2 of P97, that mediate adherence by binding to heparin 
(69–71).  An inactivated, adjuvanted whole-cell bacterin is frequently used in efforts to control 
infection, however the efficacy of the vaccine is dependent upon many factors including the age 
of infection and variation between isolates and herds (72, 73).  Experimental studies in mice on a 
recently developed chimeric protein composed of four M. hyopneumoniae antigens; P97R1, P46, 
P95, and P42 resulted in the production of specific IgG antibodies, warranting further study as a 
vaccine candidate (74). 
 M. hyorhinis is typically found in the mucous membranes of the upper respiratory tract 
and the tonsils.  While it can be present without disease, M. hyorhinis sometimes spreads to the 
lungs and contributes to pneumonia in piglets (10, 75).  More commonly, however, it is known to 
cause serofibrinous to fibrinopurlent polyserositis and arthritis in swine (10). Interestingly, M. 
hyorhinis, once thought to be non-pathogenic in humans, has been detected in human gastric, 
lung, and pancreatic cancers.  Furthermore, it has been shown to contribute to epithelial cell 
transformation (76) and promote cell migration and invasion through activation of the PI3-
kinase-AKT signaling pathway upon binding of lipoprotein P37 and the production of IL-1β and 
LI-18 due to NLRP inflammasome activation (77, 78).  A recent study assessing the metabolism 
of swine Mycoplasmas has suggested that the wider carbohydrate uptake of M. hyorhinis may 
contribute to its ability to colonize different body sites and hosts (79). 
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Mycoplasmas of Bovines 
 
 First described by Nocard and Roux in 1898, Mycoplasma mycoides subs. Mycoides 
Small Colony (MMMSC) is the etiological agent of contagious bovine pleuropneumonia (CBPP) 
(13, 80).  CBPP is the only animal disease belonging to the A list of most severe infectious 
animal diseases, can spread rapidly, and is responsible for significant socio-economic loss in 
Africa, impacts international trade, and remains a threat internationally (81).  Commercial 
vaccines currently available are live attenuated strains that may revert to virulence and require 
yearly boosting, therefore, efforts to develop improved vaccines continues (82).  MMMSC 
possesses variable surface proteins (Vmm), that undergo high-frequency phase variation (83), as 
seen in many Mycoplasma species, and that different Vmm-type proteins are shown to elicit 
antibody responses of varying strengths (84).  A recent clinical trial used a recombinant antigen 
vaccine candidate containing of Vmm and four immunogenic lipoproteins, however, only a weak 
humoral response was observed (85).  L-α-glycerophosphate oxidase (GlpO) is a membrane-
located enzyme of MMMSC involved in the metabolism of glycerol that yields toxic by-products 
such as H2O2 resulting in epithelial cell death (86, 87).  Further assessment of the glpO gene 
suggested that removing its binding site would likely attenuate the cytotoxic capabilities of 
MMMSC, and has offered a point of research for future vaccine development (88).   
 Mycoplasma bovis causes chronic pneumonia and polyarthritis syndrome (CPPS), 
mastitis, conjunctivitis, otitis media, and meningitis, resulting in significant economic loss in 
North America and Europe (89, 90).  M. bovis contains a membrane associated polysaccharide 
that acts as an inflammatory toxin which results in eosinophilic mastitis when inoculated into the 
udder (91).  It has also been reported that M. bovis, like many Mycoplasmas, possess variable 
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surface lipoproteins.  However, their vsp gene complex is modified, providing them with a 
greater capacity for antigenic variation (92).  It is thought that M. bovis does not induce 
neutrophil extracellular traps which likely serves as a survival mechanism (93).  Most of the 
current vaccines available for M. bovis are bacterins or recombinant proteins that offer varied 
levels of protection. Recent research on vaccine candidates utilizing different antigens in 
combination with adjuvants is ongoing (94). 
 
Mycoplasmas of Caprines and Ovines 
 
 Mycoplasma capricolum subsp. capripneumoniae commonly causes contagious caprine 
pleuropneumoniae (CCPP) resulting in high mortality rates in goats.  It is also known to cause 
arthritis, mastitis, and septicemia, causing significant economic loss in Africa and Asia (95, 96).  
Belonging to the Mycoplasma mycoides cluster, M. capricolum subsp. capripneumoniae is 
closely related to the less pathogenic M. capricolum subsp. capricolum.  Both subspecies are 
genetically very similar to other members of the M. mycoides cluster which has made 
detection/identification difficult.  Genetic evaluation determined differences found within the 
lipoprotein gene lppA is truncated in subsp. capricolum suggesting it may be a virulence factor 
(96).   
 Mycoplasma agalactiae causes mastitis, arthritis, keratoconjunctivitis, and pneumoniae, 
known as contagious agalactia, in sheep and goats (95, 97).  M. agalactiae is transmitted 
vertically from doe to kid during suckling, and is frequently isolated from milk samples of 
infected animals (98).  Attempts to control M. agalactiae/contagious agalactia through the use of 
vaccines and antibiotics have been able to reduce the appearance of new clinical signs and 
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mycoplasmal excretion, however, they are unable to prevent transmission (99).  Known 
virulence factors of M. agalactiae include biofilm formation (100), production of hydrogen 
peroxide (101), and two homologues of nitrogen fixation proteins, NifS and NifU, which may 
enable adaptation to different growth conditions (97).  
 
Mycoplasmas of Rodents 
 
 Mycoplasma pulmonis is a respiratory pathogen of rats and mice that causes respiratory 
mycoplasmosis, similar to atypical pneumonia in humans, and can induce changes associated 
with allergic airway disease and airway hyper-reactivity due to production of Th2 cytokines 
(102, 103).  Characteristics of M. pulmonis that likely contribute to survivability within the host 
include biofilm formation (104, 105), and phase variation of surface lipoproteins (Vsa) to assist 
in evading the host immune response (106) and modulate adherence to pulmonary epithelial cells 
(107).  Predicted virulence factors, based on the ability of other Mycoplasmas to produce 
hydrogen peroxide, include the secretion of the nuclease hemolysin, and glycoprotease (108).  
Studies on the immune response to M. pulmonis have indicated the importance of Toll-like 
receptor 2 (TLR-2) signaling in both the pathogenesis and clearance of the organism; it appears 
to be critical for airway mucin expression (20), but also results in decreased bacterial load when 
compared to TLR-2 knockout mice (109). 
 Mycoplasma arthritidis is a natural pathogen found in rats that causes severe 
polyarthritis, and has been shown experimentally to induce chronic proliferative arthritis in mice 
(110).  Perhaps the most well-known characteristic of M. arthritidis is the M. arthritidis mitogen 
(MAM): considered to be a model superantigen (Sag).  MAM acts on multiple immune cells 
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including T-cells, B-cells, NK cells and macrophages, presented via MHC class II on accessory 
cell surfaces (111, 112).  This Sag plays an important role in toxicity and dermal necrosis; it has 
been shown that mouse strains with highly susceptible lymphocytes, when activated by MAM, 
develop a suppurative abscess which may lead to coagulative necrosis of the dermis(112).  It is 
likely that the interaction of MAM with TLR-2 and TLR-4 differentially upregulates co-
stimulatory molecule B7-1 on T-cells and therefore alters the cytokine response to M. arthritidis 
(113). 
 
Mycoplasmas of Felines 
 
 Mycoplasma felis was originally isolated from a severe case of conjunctivitis in a cat 
(114).  While this Mycoplasma can be found in normal conjunctival tissue, it is recommended 
that cats presenting with conjunctivitis who test negative for Chlamydophila felis and feline 
herpesvirus (FHV-1) should be further assessed for M. felis (115).  M. felis is also associated 
with severe respiratory disease (116).  Both diseases appear to occur more commonly in kittens 
than adult cats (115, 116).  More recently, M. felis was isolated from bronchoalveolar lavage 
fluid samples of healthy cats as well as those suffering from feline asthma and chronic 
bronchitis.  Further study is needed to determine whether M. felis may contribute to the 
exacerbation of these diseases, or whether this mycoplasma may represent a commensal 
organism of the lower respiratory tract of felines (117). 
 Erosive polyarthritis in cats is associated with Mycoplasma gateae. The organism was 
isolated strictly from the synovial fluid of affected cats, however, its pathogenesis and potential 
role in disease progression is not well known (118).   
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Mycoplasmas of Canines 
 
 There are over 15 species of Mycoplasmas that have been isolated from canines over the 
past 70 years.  They form part of the normal bacterial flora in the upper respiratory tract, 
however Mycoplasma cynos, is the only species found in the lungs of dogs that is thought to 
exacerbate canine infectious respiratory disease (CIRD) (119, 120).  A recent study on the 
prevalence of M. cynos in shelter dogs has shown that a high percentage of asymptomatic dogs 
harbor CIRD- associated pathogens including M. cynos (121). Other species isolated from the 
dog during pneumonia include M. bovigenitalium, M. canis, M. edwardii, M. feliminutum, M. 
gateae, and M.  spumans (120).  M. canis is also associated with urogenital disease and infertility 
and has been isolated from the prostate, epididymis and the bladder wall even after antibiotic 
therapy. Anemia in dogs is associated with M. haemocanis infection in immune-compromised 
animals.  Mycoplasma sp. Strain HRC689 is part of the normal flora found within the colon, 
though it is questioned whether it may play a role in colitis (119).  Little is known about the 
pathogenicity and virulence factors of canine mycoplasmas, though it has recently been shown 
that M. cynos, M. canis, and M. molare, secrete sialidase by catalyzing the hydrolysis of α-(2-3)-, 
α-(2-6)-, and α-(2-8)- glycosidic linkages of terminal sialic residues .  This is a unique 
characteristic of these species, as other species such as M. gallisepticum and M. synoviae contain 
membrane-bound sialidase (122, 123).  Sialidase activity was first thought to contribute to 
virulence after transposon insertion mutation in the sialidase gene of M. gallisepticum resulted in 
decreased lesions and recovery of the organism (124).  Association with virulence was also been 
shown in M. synoviae where strains with greater sialidase activity were more virulent (125). 
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Further analysis is needed to determine whether secreted sialidase from these canine 
mycoplasmas contributes their pathogenesis. 
 
Mycoplasmas of Reptiles and Piscines 
 
 In 1995, there was an epidemic in captive American alligators of pneumonia, pericarditis, 
and multifocal arthritis.  It was not until four years later that an experimental infection study 
identified flesh-eating Mycoplasma alligatoris as the etiologic agent of the epidemic (126).  
Pathologic changes associated with M. alligatoris include fibrinous polyserositis and 
polyarthritis, with the severe and sudden inflammation leading to death (126).  M. alligatoris was 
found to have genes encoding hyaluronidase and sialidase.  These likely act as spreading factors 
when degrading the extracellular matrix (ECM), have been shown to promote CD-95 mediated 
fibroblast apoptosis, and therefore contribute to the virulence of this organism (127, 128). 
 Mycoplasma crocodyli, sharing 98% 16S rRNA gene similarity with M. alligatoris, 
causes necrotizing synovitis, and in some cases, subacute pneumonia in Nile crocodiles (129, 
130). This mycoplasma shows reduced virulence compared to M. alligatoris which may, in part, 
be due to the lack of sialidase activity (130).  Another reptilian Mycoplasma identified around 
the same time as M. alligatoris is M. agassizii, which causes an upper respiratory tract disease in 
the desert tortoise (131, 132).  
 Mycoplasma mobile, the only known mycoplasma to infect fish, causes necrosis of the 
gills (133).  This mycoplasma is one of 12 known species to have gliding motility, though the 
speed of its motility is considerably faster than the average speed of others including M. 
pulmonis, M. pneumoniae, M. genitalium, and M. gallisepticum (134).  The molecule Gli349, 
 18 
distributed around the cell neck of the organism, is responsible for cytadherence during gliding 
(135) as described by the ‘centipede model’ which relies on the ATP-dependent binding and 
subsequent conformational change that moves the mycoplasma forward (136).  Further analysis 
of their gliding motility has identified Gli521 as the protein involved in the generation of a tilted 
propulsive force with a curved trajectory (137, 138). 
 
Mycoplasmas of Avians 
 
 Mycoplasma synoviae is known for causing infectious synovitis in chickens and turkeys.  
It has also been associated with respiratory disease, though, depending on the strain, these 
infections are usually subclinical (139, 140).  Decreased egg production and the observation of 
Eggshell Apex Abnormality (EAA) has motivated research on the potential association whether 
M. synoviae infects the oviducts and affects eggshell formation, though little evidence currently 
exists to support this notion (141).  Infectious arthritis is still poorly understood, though it was 
recently shown that M. synoviae results in apoptosis of chondrocytes by upregulating genes 
involved in nitrous oxide production, caspase 3 activation, and mitochondrial inactivation (142).  
Virulence factors likely include phase variable vlhA lipoproteins which may assist in evading the 
host immune response (143), and sialidase activity (124).  While the pathogenesis of this 
organism is not completely understood, a live attenuated vaccine (strain MS-H) was developed 
that elicits a systemic, humoral antibody response which prevents colonization (144, 145).   
 Mycoplasma iowae, a significant pathogen in turkey breeder hens, causes late embryo 
mortality, reduced hatchability, leg abnormalities, and may be involved in chondrodystrophy 
(146–148).  Upon experimental infection of chickens and turkeys, airsacculitis, tenosynovitis, 
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arthritis, rupture of digital flexor tendons, and cartilage erosion was observed (148).  
Interestingly, dead-in-shell embryos showed colonization in the genital tract, respiratory tract 
and bursae, indicating the capability of M. iowae to survive in multiple organ systems (149).  As 
seen in numerous mycoplasmas, M. iowae is capable of phenotypic variation which may 
contribute to host immune evasion and its ability to establish chronic infection (149).  It has also 
been found that M. iowae encodes the gene katE, an active catalase that is known to be capable 
of degrading H2O2, which may increase its survivability (150, 151).  When found in the intestinal 
tract, M. iowae does not cause disease; this may be due to the decreased expression of a CARDS-
like toxin producing gene that occurs in when colonizing tissues with low atmospheric oxygen 
(150).   
 There are several other avian mycoplasma species that have been identified including M. 
gallinarum that infects chickens, pheasants, geese and sparrows, and M. gallopavonis that infects 
turkeys: both resulting in mild respiratory symptoms.  M. meleagridis infection of turkeys causes 
sinusitis, airsacculitis and infection of the genital tract.  In pigeons, M. columbinasale and M. 
columborale results in rhinitis and pharyngitis (152). 
 
 
 
Section 3: Mycoplasma Host Interaction 
 
 Mycoplasmas have the ability to colonize and often establish chronic infection in a 
variety of tissues within different hosts despite having small genomes and limited metabolic 
capabilities.  Their survivability is highly dependent on the interaction with the host, for which 
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they have various strategies used in disease pathogenesis and persistence while exposed to the 
host immune response.  
 
Cytadhesion and Gliding Motility 
 
 Cytadhesion of mycoplasmas to host cells is a prerequisite for colonization and is 
important in the motility, virulence and pathogenesis of the organism.  The structure is also 
important to adherence capabilities as mycoplasmas are generally flask shaped with cytadhesion 
occurring at ‘tip organelle’ located on the leading end.  This organelle is composed of an electron 
dense core and contains a high concentration of adhesin molecules (2, 153, 154).  The 
cytadhesion capabilities of M. pneumoniae have been the most extensively studied to date.  The 
primary adhesin molecule protein P1 is assisted by P30, a protein that is known to be important 
in cell development, both of which are required for M. pneumoniae to adhere to respiratory 
epithelia (155–158).  It is important to note that both P1 and P30 elicit strong immunological 
responses.  Additionally, P30 shares sequence homology with eukaryotic structural proteins such 
as fibrinogen, keratin, and myosin, suggestive of molecular mimicry which may result in 
autoimmunity (155, 156).  The P1 and P30 molecules are localized in the tip organelle, along 
with other molecules thought to be associated with cytadhesion.  These include P40 and P90, and 
high-molecular-weight cytoskeleton proteins HMW1-HMW3 known to maintain proper 
distribution of the adhesin proteins. Their role was further elucidated when mutants lacking any 
one of these proteins were unable to cytadhere (2, 153, 159, 160).   
 Several mycoplasmas are known to possess cytadhesion molecules including M. 
hyopneumoniae (69–71), M. mobile (135), M. agalactiae (100), and M. hominis (161).  However, 
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only M. gallisepticum and M. genitalium contain molecules with significant sequence homology 
to P1 of M. pneumoniae; GapA and MgPa, respectively (162–164).  GapA is the primary 
cytadhesion molecule of M. gallisepticum and an important factor in virulence, as strains lacking 
the molecule were found to be avirulent in comparison (164, 165).  Further sequence analysis 
revealed another molecule (CrmA) encoded within the gapA operon that is essential for 
cytadherence and pathogenesis (166).  Interestingly, crmA shares sequence homology with the 
ORF6 gene of M. pneumoniae which encodes a protein that is cleaved into cytadhesion 
molecules P40 and P90 (167).  Other mechanisms that have been implicated in assisting 
cytadhesion include the ecto-ATPase activity of cytadhesin OppA in M. hominis (168).   
 Cytadherence is also involved in the immune response to mycoplasmas.  M. pneumoniae 
was shown to induce cytadherence-dependent production of pro-inflammatory cytokines such as 
TNF-α and IL-1β due to M. pneumoniae lipoproteins such as P1, ligating TLR-2 receptors of 
monocytes in vitro (169). Lipoproteins isolated from M. gallisepticum have also been shown to 
increase the production of proinflammatory cytokines through the ligation of TLR-2 (170). 
Additionally, it has been observed that cytadhesion of M. pneumoniae induces autophagy-
dependent TLR-4 signaling (171).  Studies on vaccine development for mycoplasma infections 
have included mimic epitopes of M. genitalium and recombinant adhesion proteins of M. suis in 
attempt to induce a protective immune response (172, 173).   
 The ability to cytadhere coupled with the flask-like morphology enables mycoplasmas to 
move on solid surfaces in a unique process known as gliding motility (155, 174).  Not all 
pathogenic mycoplasmas have gliding motility, however, those that do including M. pneumoniae, 
M. genitalium, M. penetrans, M. mobile and M. gallisepticum, motility has been indicated as an 
important virulence factor (174, 175).  Adhesion molecules P1 and P30 of M. pneumoniae were 
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shown to be important in gliding motility as seen when anti-P1 monoclonal antibodies and 
deletions or substitutions within the P30 domain had inhibitory effects on motility (137, 176).  
MG200 and MG249 of M. genitalium (177), Gli521 and Gli349 of M. mobile (138), and GapA 
and CrmA of M. gallisepticum (178) are critical proteins involved in their motility. Most 
mycoplasmas utilize energy from ATP hydrolysis as reflected by the fact that depletion of ATP 
inhibited M. mobile motility (179).  However, M. penetrans may be unique as it has shown to be 
able to use energy derived from temperature: in an environment depleted cellular ATP, 
increasing temperature increased the speed of gliding motility (180). While not yet identified, 
this suggests the potential for polarized polymerization of the cytoskeleton (180). Cytadhesion 
and gliding motility enable mycoplasmas to escape mucociliary clearance and to maintain close 
proximity to host cells, and therefore, play significant roles in the pathogenesis of these 
organisms.  
 
Invasion of Host Cells 
 
 Mycoplasmas are generally considered to be extracellular pathogens as they are found to 
cytadhere and colonize the mucosal surfaces of their hosts.  However, several mycoplasmas have 
been found in multiple locations/organ systems, and some have mechanisms for entering non-
phagocytic host cells (155).  These include M. bovis, M. suis, M. agalactiae, M. fermentens, M. 
hyorhinis, M. hominis, M. penetrans, M. genitalium, and M. gallisepticum (181–194).  The first 
mycoplasma thought to invade host cells was M. penetrans as it was found to survive within host 
cells of the urogenital tract in AIDS patients (192), and has recently been shown to invade and 
survive in HeLa cells (185, 195).  M. gallisepticum was shown to invade human epithelial cells 
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and chicken embryo fibroblasts in vitro (182).  After experimental aerosol inoculation of 
chickens with M. gallisepticum, virulent strain Rlow was re-isolated from the heart, brain, liver, 
spleen, and kidney (189) and was also detected within erythrocytes sampled directly from the 
bloodstream (190).  This suggests, that once M. gallisepticum crossed the mucosal barrier, it was 
able to disseminate intercellularly through the blood stream.  While eukaryotic cell invasion was 
not directly observed, there was a positive correlation between respiratory infection and 
reisolation from internal organs (189). Most recently it was demonstrated that components of the 
host extracellular matrix (ECM) including type IV collagen, plasminogen and fibronectin, were 
necessary for M. gallisepticum to invade host cells (196). While these components are likely 
exposed during the pathogenesis of M. gallisepticum within the chicken trachea, evidence of 
tracheal epithelial cell invasion has not been seen. 
 
Host Cell Receptors 
 
 Sialoglycoconjugates on the surface of the host cell have been established as receptors for 
M. pneumoniae, M. genitalium, M. synoviae, and M. gallisepticum (197). The adhesion of M. 
pneumoniae via adhesin molecule P1 to cultured erythrocytes and lung fibroblasts is mediated 
through sulfated glycolipids and glycoproteins containing α2-3-linked sialic acid (198, 199).   
Cilia also plays an important role in the adhesion and pathogenesis of mycoplasmas in the 
respiratory epithelium.  M. hyopneumoniae, known to colonize the surface of ciliated cells in the 
trachea and bronchi, bind host glycolipid receptors (200) with outer membrane adhesion 
molecules P97, P159, Mhp384, and Mhp385 (201, 202).  The importance of cilia was further 
supported when M. pneumoniae accessed the base of the cilia utilizing gliding motility to 
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penetrate the mucuosal barrier.  Tethered mucins where shown to not only support the mucus 
barrier, but enabled better gliding motility once the initial barrier was breached (203).  
Cytadhesion was markedly reduced upon squamous metaplasia, or the exposure of basal cells 
during cellular growth/turnover or as a host defense mechanism (203, 204).  However, several 
surface exposed proteins of mycoplasmas have shown the ability to bind components of the ECM 
including plasminogen, fibronectin, and heparin, which may become exposed during the 
pathogenesis of mycoplasma infection (205).  In M. gallisepticum, for example, has shown to 
bind fibronectin with their HMW3 homologue (206), binds heparin through an OsmC-like 
protein (207), and fibronectin with PlpA (208). While mycoplasmas have been shown to bind 
these components, definitive evidence that they contribute to cytadherence and subsequent 
colonization is still needed. 
Mycoplasma have also been shown to result in ciliostasis; likely allowing better access to 
the base of the cilia (209).  Further damage to cilia in the presence of cytadherent mycoplasma 
results in loss of cilia may benefit the host by limiting suitable binding cites (209), the typical 
host defense mechanisms including mucus production and ciliary clearance have therefore been 
shown to be ineffective at clearing mycoplasmas.   
 
Mycoplasma Lipoproteins 
 
 Mycoplasmas are only enveloped by a plasma membrane, and therefore, do not contain 
lipopolysaccharides (LPS), lipotechoic acid, peptidoglycan, or flagella: the typical pathogen 
associated molecular pattern (PAMP) molecules that are frequently target by and interact with 
host cell receptors.  Instead, mycoplasmas contain numerous lipoproteins, also known as lipid 
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associated membrane proteins (LAMPs), anchored within the plasma membrane (155, 210).  A 
significant percentage of the mycoplasma genome encodes lipoproteins; in M. gallisepticum, 
variable lipoprotein hemagglutinins (VlhA) encoding genes accounts for 10.4% of their total 
genome (167).  Several LAMPs are typically expressed by mycoplasmas at any one time.  Many 
of these LAMPs are in close contact with host cells, likely acting as antigens, and may serve as 
immunomodulins contributing to pathogenesis (211).  Ligation of pattern recognition receptors 
(PRRs) of the innate immune system include Toll-like receptors (TLRs) and NOD-like receptors 
(NLRs) (212).   
 Numerous studies have implicated mycoplasma lipoproteins in the activation of the 
innate immune response and subsequent production of chemokines and cytokines. Lipoproteins 
are well known to ligate TLRs 1, 2, 6, (213) and TLR 15 specific to avian and reptilian species 
(214).  Lipoprotein macrophage activating lipopeptide-2 (MALP-2) of M. fermentans and a 44 
kDa lipoprotein from M. salivarium were the first found to interact with host TLR and activate 
the immune response as evidence by production of macrophage inflammatory protein-1α (MIP-
1α) (215, 216).  The structure of mycoplasma lipoproteins has also proven to be important.  Tri-
acylated lipoproteins ligate TLR-1/2 heterodimers and diacylated lipoproteins ligate TLR-2/6 
heterodimers, sometimes requiring CD14, all indicating the importance of the MyD88-dpendent 
signaling pathway.  Additionally, the N-terminal lipid moiety was found to be responsible for 
activation of NF-κB and subsequent production of pro-inflammatory cytokines (53, 169, 217–
220).  The greater understanding of the interaction between mycoplasma lipoproteins and TLRs 
promoted research in several mycoplasmas such as M. genitalium, M. bovis, M. fermentans, M. 
pneumoniae, M. synoviae, and M. gallisepticum which further elucidated the role of cytokines 
and chemokines in the pathogenesis (28, 170, 218, 221–225).  In chickens, in vivo analysis 
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showed that experimental infection of M. gallisepticum within the trachea induced the 
production of pro-inflammatory cytokines and chemokines such as IL-6, IL-8, CCL20, CXCL-
13, CXCL-14, and RANTES (224), this pro-inflammatory response was further substantiated 
when LAMPs from M. gallisepticum resulted in the upregulation of IL-1β, IL-6, IL-8, IL-12p40, 
CCL20, and NOS-2 in cultured tracheal epithelial cells through an NF-κB dependent pathway 
via TLR-2 (170).   
 Ligation of mycoplasma lipoproteins to TLRs has also been shown to induce apoptosis 
and necrosis of host cells.  M. salivarium and M. fermentans lipoproteins induced necrotic cell 
death in lymphocytic and monocytic cell lines, and induced necrosis or apoptosis of monocytic 
cell lines.  Both functions were found to be dependent on caspase activation and TLR-2 ligation 
(62, 226, 227).  The induction of ATP release from host cells after lipoprotein ligation has also 
been shown to result in host cell apoptosis in M. salivarium, M. fermentans, and M. hominis.  
Extracellular ATP (ATPe) binds purinergic receptors such as P2X7 and P2Y1 on host cells that 
activate leukocytes (62, 227–229) and epithelial cells (230).  Binding of ATP to these receptors 
results in the release of activated caspase 1 in the inflammasome and subsequent release of 
mature IL-1β (231, 232).  This indicates another pathway induced and pathogenic mechanism of 
mycoplasma lipoproteins. 
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Section 4: Host Immune Response to Mycoplasma 
 
Induction of Innate Immune Response 
  
 The host’s initial encounter with mycoplasmas typically occurs with the epithelial cells of 
the mucosal tissues of the respiratory, reproductive or conjunctiva.  As discussed above, gliding 
motility and/or the capability to cytadhere to host cell receptors enables mycoplasmas to 
successfully colonize and often times result in pathogenesis.  The proximity to the host cells 
enables lipoproteins anchored within the membrane of mycoplasmas, acting as PAMPs, to ligate 
PRRs such as TLRs and NLRs important in recognizing the presence of the bacteria subsequent 
pro-inflammatory signaling (233).   
 Factors such as nuclear or cytosolic proteins and ATP are also involved in the innate 
immune response by acting as DAMPs that ligate to nucleotide binding oligomerization domain 
(NOD) -like receptors (NLRs).  Ligation and subsequent activation of the NLR pathway can 
result in the production of chemokines and pro-inflammatory cytokines, as well as activation of 
the inflammasome.  Extracellular release of ATP has been shown to occur in the presence of 
mycoplasmas resulting in the activation of the Nlrp-3 inflammasome due to the ligation of ATP 
to the P2X7 purinergic receptor. Activation of the inflammasome resulted in increased 
production of IL-1β (62, 228, 229).  Inflammasome activation during host defense typically 
occurs in macrophages, as was seen when lipoproteins of M. fermentans and M. salivarium and 
the presence of extracellular ATP acted synergistically to activate macrophage inflammasomes 
(62).  However, inflammasomes have been shown to become activated in respiratory epithelium 
(234, 235).  Recently, M. pneumoniae CARDS toxin was shown to regulate inflammasome 
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activity through bacterial ADP-ribosylation, resulting in activation of the Nlrp-3 inflammasome 
(236). 
 The role of type-1 macrophages as mediators of inflammation through antigen 
presentation has shown to be limited during mycoplasma infection.  Early studies showed that 
peritoneal macrophages attached to M. pulmonis without hindering the growth of the M. 
pulmonis population (237), while others showed that M. pulmonis was in fact phagocytized by 
peritoneal macrophages (238).  A study assessing the virulence of M. pulmonis strains based it 
on the ability of the organism to survive in the respiratory tract, induce pneumonia, and persist in 
the peritoneal cavity.  These factors were largely based on the ability of these strains to resist 
killing by macrophages. Strains that evaded phagocytosis typically resulted in exacerbated 
disease (239).  A recent study showed that the ability of M. pulmonis to evade alveolar 
macrophages was dependent on the length of their Vsa lipoproteins: long Vsa lipoproteins 
containing tandem repeats prevented macrophage binding (240).  They further explained that the 
previous studies were not able to replicate this observation in part  because they exposed 
macrophages to M. pulmonis that had been grown in a biofilm, which yields  shorter lipoproteins 
(240).   
 Mycoplasma induced lesions in the early course of infection largely consist of 
neutrophils/heterophils, depending on the host  species.  Previous studies assessing the interplay 
between neutrophils and M. pneumoniae, M. hominis, and M. salivarium suggested that 
neutrophils spontaneously bind mycoplasmas through complement receptors, activate C1 of the 
complement system, but without the prior opsonization by antibody, they remained viable within 
the neutrophil upon phagocytosis (241).  An important role that neutrophils play during 
microbial infection is the release of neutrophil extracellular traps (NETs) composed of 
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antimicrobial peptides and enzymes. Assessment of mammary glands infected with M. 
agalactiae confirmed that NETs were released during mycoplasma infection, and further 
determined that this could be induced by the interaction of mycoplasma lipoproteins with 
neutrophils (242).  Production of reactive oxygen species (ROS) by neutrophils is thought to be a 
necessary preliminary step prior to the release of NETs.  ROS production was found to be 
prevented upon exposure to M. bovis which also prevented the NET release (243).  Furthermore, 
it has been observed that M. bovis enhances neutrophil apoptosis, inhibits nitic oxide production, 
and increases neutrophil elastase production known for degrading the extracellular matrix which 
may represent an attempt to clear the pathogen (244).  However, long-term survival of M. bovis 
has been found in necrotic lesions despite the presence of neutrophils and macrophages (245).  
Interestingly, M. pneumoniae was shown to induce the release of a cathelin-related antimicrobial 
peptide (CRAMP) from neutrophils which may be able to kill the organism.  However, M. 
pneumoniae produces Mpn491, a nuclease that has been shown to degrade other components of 
NETs (246).  These studies indicate that neutrophils may not be very effective at eliminating 
mycoplasma infection, and due to the release of histamines as seen in M. pneumoniae infection, 
neutrophils may further contribute to lung and airway inflammation (247). 
 Natural killer (NK) cell activity has been enhanced by some species of mycoplasma. The 
lytic capability if human NK cells was augmented both directly and indirectly due to cytokines 
produced by T cells (248).  M. pulmonis infection resulted in splenic and pulmonary NK cell 
activity and indicated that exacerbation of disease occurred upon NK cell depletion (249).  
However, it was found that NK cell depletion at the time of a nasal-pulmonary vaccine against 
M. pulmonis resulted in a stronger adaptive immune response, and the presence of NK cells at 
the time of vaccination skewed cytokine production resulting in higher IL-4, IL-13 and IL-17 
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(250).  Activation of TLR-2 signaling with M. fermentans lipoprotein MALP-2 was not able to 
induce NK cell activation (251). 
 
The Role of Chemokines and Cytokines 
 
 Colonization of the mucosal epithelium by pathogens results in the production of 
chemokines and cytokines by epithelial cells in contact with the pathogen.  This results in the 
recruitment and activation of innate immune cells including neutrophils (heterophils in avian 
species), macrophages, natural killer (NK) cells, dendritic cells, eosinophils and basophils to the 
mucosa (233).  The intended purpose of these cytokines and chemokines is host defense, 
however in many instances, as seen in the response to mycoplasmas, they contribute to the 
manifestation and immunopathology observed in chronic disease. 
 Human cultured endocervical epithelial cells exposed to Mycoplasma genitalium were 
found to produce IL-6, IL-7, IL-8, MCP-1 and GM-CSF during early infection, and IL-8, MIP-
1β and MCP-1 during late stage infection (220, 252, 253).  Experimental infection of pigs with 
M. hyopneumoniae showed increased expression if IL-5 and IL-13 in both epithelial and 
mononuclear cells (254).  Patients infected with M. pneumoniae showed increased expression of 
IL-8 and RANTES in nasal epithelial cells, while in vitro analysis using adenocarcinomic human 
alveolar basal epithelial cells (A549) showed increased expression of IL-1β, IL-8 and TNF-α 
(255).  Cultured tracheal epithelial cells exposed to M. gallisepticum LAMPs resulted in the 
transient upregulation of several cytokines and chemokines including IL-1β, IL-6, IL-8, IL-
12p40, CCL20, and NOS-2 (170).  The cytokines and chemokines observed in these studies are 
well known for the activation and recruitment of leukocytes. 
 31 
 Mycoplasmas have also induced the production of chemokines and/or cytokines by 
inflammatory cells, further contributing to disease outcome.  LAMPs were shown to induce 
production TNF-α, IL-1β and MIP-1β upon infection with mycoplasmas including M. 
pneumoniae, M. gallisepticum, M. fermentans and M. penetrans (53, 169, 171, 217, 221, 256).  
The chemotaxis of inflammatory cells into the lamina propria often results in gross inflammatory 
lesions and subsequent increased production of cytokines including, but not limited to IL-1β, IL-
4, IL-5, IL-6, IL-17A, IFN-γ, and TNF-α as seen in infection with M. pulmonis and M. mycoides 
subsp. mycoides (257–259).  The cytokines and chemokines produced can significantly impact 
the balance between Th1,Th2, and Th17 responses.  A predominant Th1 response is associated 
with a strong pro-inflammatory response associated with cell mediated immunity and production 
of cytokines such as IFN-γ capable of exacerbating disease. A Th2 response is associated with 
humoral immunity and allergic inflammatory responses through the production of cytokines 
including IL-4.  Th17 results in a pro-inflammatory response associated with bacterial infections, 
autoimmunity, and the production of cytokines such as IL-23 and IL-17 (260). M. pneumoniae 
infection has been shown to induce a significant increase in IL-4, suggesting a Th2 response 
(261), though vaccine-mediated exacerbation upon M. pneumoniae infection yielding increased 
IL-17 and eosinophilia (33).  Furthermore, while IL-6, IL-10, IL-17A and TGF-β were increased 
using the mouse model for M. pnuemoniae, it was suggested that Treg and IL-10 are involved in 
the suppression of IL-17A production which may interrupt the Th1/Th2/Th17 balance (262).  
While another study showed that M. pneumoniae induced macrophage production of IL-23 was 
required for IL-17 production by CD4+ T cells (260).  Patients with pneumonia due to infection 
with M. pneumoniae showed increased expression of both Th1 and Th2 cytokines including IL-
2, IL-4, IL-6, IL-10, TNF-α, and IFN-γ (261, 263).  In contrast, M. gallisepticum, known to 
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cause chronic respiratory disease in chickens, results in increased expression of Th1 cytokine 
genes including those resulting in IL-1β, IL-6, IL-8, and IL-12p40 (170, 224).  These data further 
emphasize the importance of cytokine and chemokine production as a result of mycoplasma 
infection and the role they can play in host defense or the development of immunopathologic 
conditions. 
 
Adaptive Response to Mycoplasma Infection 
 
 Activation of the adaptive immune response is a complex and specialized process 
involving antigen presentation initiated by cells of the innate immune system, including 
macrophages and dendritic cells, to T- and B- lymphocytes to induce adaptive immunity.  The 
adaptive immune response to mycoplasma infection is still poorly understood. While an antibody 
response is significant in limiting disease progression, many mycoplasmas have mechanisms to 
evade or counteract this host defense.  Most mycoplasmas are extracellular pathogens with 
questionable efficacy of antigen presentation.  Because of this, a significant mediator of the 
adaptive immune response during mycoplasma infection is the production of cytokines and 
chemokines. Therefore, the ability of the innate response to activate adaptive immunity largely 
dictates the whether the host response will be effective in mycoplasma clearance, or result in 
immunopathology and further exacerbation of disease.   
 Lesions composed of T and B cells are found in the tracheal mucosa and bronchus- 
associated lymphoid tissue (BALT) of the lungs resulting from persistent mycoplasma infection 
at the mucosal surface (264).  As seen in M. mycoides ssp. Mycoides, M. capricolum, M. 
agalactiae, and M. bovis, these populations are largely composed of CD4+ and CD8+ T cells, 
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with CD4+ T cells outnumbering CD8+ T cells 2 to 1 (264, 265).  Mice infected with M. 
pulmonis were found to have and increased T cell populations in the lungs and lymph nodes of 
the lower respiratory tract, with greater numbers of CD4+ T cells than CD8+.  Th1 responses 
were dominant in the spleen, with a mix of Th1 and Th2 (skewed Th1) in the lungs producing 
both IL-4 and IFN-γ cytokines.  Depletion of CD8+ cells in vivo resulted in disease exacerbation, 
while CD4+ depletion reduced the severity of disease (266).   Neither condition reduced the 
mycoplasma population, however, it showed that production of IFN-γ by CD8+ T cells can play 
an important role during infection with an extra-cellular mycoplasma (249).  Differences have 
been observed in the IFN-γ (Th1 response) and IL-4 (Th2 response) cytokine requirements in the 
upper and lower respiratory tracts. In the upper respiratory tract, loss of either cytokine did not 
appear to have an impact on mycoplasma numbers or disease pathogenesis. However, it was 
noted that there was a compensatory immune response dominated by macrophages and CD8+ T 
cells.  In the lower respiratory tract, the loss of IFN-γ resulted in increased mycoplasma numbers 
and pathogenesis (103).  Further analysis of the importance of IFN-γ and IL-4 revealed that the 
development of adaptive immunity against mycoplasma was impaired when vaccinating IFN-/- 
mice, whereas vaccinating IL-4-/- mice led to improved ability for the host to clear the 
mycoplasma (259).  These studies show that CD8+ T cells, which may contribute to IFN-γ 
production, and Th1 IFN-γ, an important macrophage activator, are important in the host 
response to mycoplasma.  While both are pro-inflammatory, they aid in preventing a Th2 skewed 
response that has shown to result in further chemotaxis of inflammatory cells in the airways as 
seen in asthma (267).   
 IL-23 activation of Th17 cells and the subsequent production of IL-17 has also shown to 
be important during mycoplasma infection.  During early M. pneumoniae infection, alveolar 
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macrophages were shown to be a significant source of IL-23 which was found to induce 
production of IL-17 by lung CD4+ T cells.  Disruption of the IL-23/IL-17 balance resulted in 
decreased neutrophil recruitment and activity, and reduced mycoplasma clearance (260).  
However, IL-17 has also been shown to be involved with disease exacerbation.  BALB/c mice 
vaccinated with an avirulent M. pneumoniae P30 mutant showed increased levels of IL-17 
corresponding with eosinophilia upon challenge with a virulent strain (33).  It has also been 
suggested that the breakdown of the immune balance between Th17/IL-17 and Treg/IL-10, as 
both IL-17 and IL-10 increased in a dose dependent manner upon repeated stimulation with M. 
pneumoniae antigens which may lead to extrapulmonary complications associated with 
mycoplasma infection (262).  Recently, it was shown that CD25+ Treg cells help to control the 
damaging immune response to respiratory mycoplasma infection by reducing lymphocyte 
infiltration into the lungs.  This response was not mediated through IL-10 or TGF-β, but instead 
was mediated by the Treg induced shift away from the Th2 response towards a Th1 response 
with associated IFN-γ and IL-17 production (268).  Therefore, it is has been suggested that the 
balance between Th1/Th2/Th17 responses to mycoplasma may be important to the progression of 
disease, however further understanding of their roles is still needed. 
 Antibody response is important in the host defense against mycoplasma, and for vaccine 
development, and may prevent dissemination of disease within a population (269).  However, 
natural infection with mycoplasma has shown a dysregulated and sometimes maladaptive 
response.  Additionally, some mycoplasma species have developed mechanisms to evade this 
response by producing chemotactic factors, proteases, and Fc receptors (270).  Different species 
of mycoplasma have been found to elicit antibody responses from all classes, with IgM being the 
first antibody generated and largely involved in the control of mycoplasma.  IgM is typically 
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followed by IgG which is able to mediate complement activation and opsonization (271).  
Because mycoplasmas are predominantly mucosal pathogens, the antibody response is 
dominated by IgA and IgG, and will occasionally result in IgE isotypes at the mucosal surface 
(272).  M. pneumoniae resistance has shown better correlation with mucosal IgA than serum IgG 
or IgM.   Similarly, early studies on the adaptive response to M. gallisepticum showed that local 
immunoglobulin titers of IgG and IgA at the mucosal surface positively correlated with 
immunity in vivo, but that serum antibodies titers did not (272).  Natural M. gallisepticum 
infection results in infiltration of lymphocytes into the lamina propria including non-specific IgG 
and IgA secreting B-cells.  Challenge after vaccination yields a more organized response with 
fewer lymphocyte infiltrates, yet contain B-cells secreting anti-mycoplasma IgG which appears 
to protect chickens from disease.  Titers of IgA were far lower than those of IgG, and it is 
thought that both may play a role in blocking initial cytadhesion (273, 274).   While IgG seems 
to play a significant role in the protection from M. gallisepticum, it is important to note that M. 
gallisepticum and M. synoviae both have the gene cysP that is shown to encode a cysteine 
protease capable of cleaving chicken IgG into Fab and Fc fragments (275).  A recent study on M. 
mycoides ssp. capri identified a complex (MIB-MIP) that this species uses to capture and cleave 
IgG.  The MIB component is the mycoplasma Ig binding protein that binds the Fv region. The 
immunoglobulin protease MIP is then recruited to cleave the immunoglobulin (276).  These 
mechanisms likely enable the prolonged survival within the host despite the antibody response 
(277). 
 Antibody response is also capable of resulting in further disease exacerbation and 
complications.  Patients with M. pneumoniae infection of the lower respiratory tract had 
comparatively higher levels of serum pro-inflammatory molecules, as well as higher Th2 
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cytokines and IgE within the lungs.  This suggested that the exacerbation of disease found with 
Th2 cytokines and IgE in the lower respiratory tract are precursors for the development of 
asthma (278).  children infected with M. pneumoniae presenting at clinic with wheeze were 
found to have increased levels of the vasoconstrictor ET-1, IL-5, and serum IgE which was 
suggestive of the exacerbation of asthma (279).  Conversely, patients without wheeze infected 
with M. pnumoniae were shown to have increased IL-5 and vascular epidermal growth factor 
(VEGF), yet similar levels of IFNγ, IL-4 and IgE as those with wheeze (280).  While there is 
some disagreement, the evidence supporting M. pneumoniae contributing to the development or 
exacerbation of asthma suggests that M. pneumoniae induced IgE production plays an important 
role.   
 Arthritis mediated by anti-mycoplasma antibodies has also been found in association with 
M. arthritidis, M. fermentans, M. hominis, M. synoviae, M. bovis, and M. pneumoniae either by 
direct infection of the synovial tissues or by antibody mediated disease.  The superantigen of M. 
arthritidis (MAM) was shown to be able to both induce arthritis and exacerbate it after 
immunization with type II collagen in mice (281).  Though it has been suggested that MAM is 
only associated with lethal toxicity and not arthritis in mice (282).  In humans, M. arthritidis has 
been found in the synovial fluid of rheumatoid arthritis (RA) patients (283).  However, there is 
inconsistent evidence whether these patients have increased IgG or IgM anti-MAM antibiodies 
(281, 284).  M. fermentens has been found in the synovial fluid of patients with RA, 
osteoarthritis, and crystal synovitis (283, 285).  In RA patients, IgM and IgG antibodies against 
M. fermentens were found more frequently in the blood than in healthy patients (286).  M. 
pneumoniae, also found in the synovial fluid of RA patients, has been associated with specific 
anti-mycoplasma IgM antibodies.  A rapid test is commercially available (ImmunoCard 
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Mycoplasma; Meridian Bioscience, Cincinatti, OH) to detect IgM anti-M. pneumoniae 
antibodies in serum.  While a limited number of patients with mycoplasma specific IgM were 
found to have arthritis (287), a study assessing reactive arthritis in children found a large 
proportion of patients having anti-M. pneumoniae IgM in their serum (288).  Immune complexes 
(IC) have been found deposited in tissues as well as circulating in the blood of mice 
experimentally infected with M. arthritidis (289), and upon purification from synovial fluid of 
RA patients, have been shone to react with proteins from various mycoplasma species (290).  
These studies have observed the association between mycoplasmas and arthritis, and have 
offered a potential mechanism (IC) by which mycoplasma may indirectly result in or contribute 
to arthritic conditions. However, further study is needed to fully appreciate their role in this 
disease.  
 
 
Mechanisms of Immune Evasion  
 
 Two characteristics of mycoplasmas that are suggested to aid in immune evasion are 
antigenic mimicry and surface variable expression of lipoproteins.  Early studies on antigenic 
mimicry of mycoplasmas observed that rabbit antisera against strains of M. arthrtidis reacted 
with a component of rat muscle tissue (291), and identified a murine monoclonal antibody 
against M. hyorhinis that reacted with mammalian intermediate filaments.  This antibody 
recognized a protein epitope of M. hyorhinis of which similar epitope components were found in 
other mycoplasmas including M. pulmonis, M. fermentans, M. hyopneumoniae, and M. 
pneumoniae, defining an antigenic structure likely important in autoantibody development (292).  
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Recently, antibodies against M. penetrans HF-2 epitopes have been used in efforts to develop a 
vaccine against melanoma due to the observed cross-reaction with MAGE-A6 expressed on 
tumor cells (293).  Both P1 and P30 adhesion molecules of M. pneumoniae have shown antigenic 
mimicry.  Monoclonal antibodies against P1 cross-reacted with human GAPDH and enolase of 
the glycolytic pathway.  It was suggested that these antigenic similarities may be responsible for 
the non-responsiveness or self-limitation of the immune response to M. pneumoniae (294).  
Further analyses determined that both P1 and P30 adhesins share homology with eukaryotic 
structural proteins including fibrinogen, keratin, myosin and actin.  This was confirmed when 
P30 antibodies cross-reacted with fibrinogen, and anti-fibrinogen antibodies bound to wild-type 
P30 (156). 
 Many mycoplasma species are capable of altering the size, structure, or expression of 
their surface proteins.  Possible reasons for the development of these mechanisms may include 
the need to avoid mechanical clearance by expressing tissue-appropriate adhesins, and avoiding 
recognition by the host immune response (295).  Strategies used to accomplish the variation 
include phase and antigenic variation and epitope masking.  Specifically, on/off switching may 
be accomplished by genetic events including DNA slippage and site-specific recombination of 
the genes or their promoters, size variation can occur via DNA slippage, base substitutions, or 
posttranslational modification, domain shuffling may occur through non-reciprocal, reciprocal 
recombination or intrachromosomal recombination with deletion (295).   
 The first described mechanism of mycoplasmas gene switching involved the molecular 
on/off switch of M. hyorhinis vlp genes due to DNA slippage in the promoter regions (296, 297).  
The surface lipoproteins of M. hyorhinis are encoded by a genetic system of 3-8 elements in the 
chromosome (298, 299).  Each vlp gene is considered a single transcription unit containing a 
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poly-A tract within the promoter region between the -35 and -10 sequences.  The Vlp is 
expressed only when the poly-A tract is 17bp long, therefore, a single insertion or deletion 
prevents transcription (297).   Size variation of expressed Vlp products through DNA slippage 
involving close repeats within coding sequences is advantageous for immune evasion.  Isogenic 
clonal variants of M. hyorhinis expressing different Vlp profiles were assessed for their 
susceptibility to growth inhibition by serum Abs of swine.  This study found that the variants 
expressing longer versions of VlpA, VlpB, or VlpC were resistant to the host serum Abs.  
Furthermore, it was determined that the Vlp products themselves were not the target of the host 
Abs, but that the long versions of Vlp were able to mask the antigen targeted by host Abs (300).  
A similar mechanism is utilized by M. gallisepticum for the expression of variable lipoprotein 
hemagglutinin (vlhA) genes.  These genes include 38 with signature vlhA features and 5 
pseudogenes possessing vlhA sequence homology, and together comprise approximately 10.4% 
of their total genome (167).  Phase variation is controlled at the transcriptional level, and was 
once thought to require 12 GAA trinucleotide repeats upstream of the -35 box for expression of a 
given vlhA to enable proper spacing between flanking sequences for accessory factors to bind 
(301–305).  However, recent transcriptional analysis has indicated that 12 GAA repeats were not 
necessary for expression of a given vlhA, and suggested that a different mechanism may be 
responsible for the regulation of vlhA expression (306).  Furthermore, a previous assessment 
found that both chicken serum antibody responses and surface antigens of M. gallisepticum 
underwent rapid change in vivo, supporting the hypothesis that the changes in vlhA expression 
may be an adaptive mechanism to evade the host immune response (307).  However, while this 
hypothesis is not directly disputed, it was later found that variation in the expression of surface 
proteins occurred in nearly 40% of cells within 2 days (302).  This was further supported by 
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transcriptional analysis which also showed changes in vlhA expression occurring as early as 2 
days post infection (306). While interaction with the host may play a role in the changes of vlhA 
expression, it remains uncertain whether the changes are mechanisms to evade host defense 
mechanisms. 
 
Section 5: Mycoplasma gallisepticum 
 
Disease and Significance 
 
 Mycoplasma gallisepticum is a significant pathogen of poultry largely affecting the 
respiratory and reproductive tracts (308).  This pathogen spreads  both horizontallyand 
vertically(309, 310), resulting in significant economic loss due to poor feed conversion 
efficiency, reduced egg production and hatchability (311, 312).  M. gallisepticum is the primary 
etiologic agent of chronic respiratory disease (CRD), though it is typically found concurrent with 
other infectious pathogens including Newcastle disease virus, Avian Influenza virus (AIV), 
infectious bronchitis, pathogenic E. coli, Haemophilius, and avian rhinotracheitis virus (313–
315).  Characteristics of M. gallisepticum infection include coughing, sneezing, nasal discharge, 
tracheal rales, increased mucus production and loss of cilia, labored breathing due to 
airsacculitis, and conjunctivitis (316, 317).  Inflammatory lesions are commonly found in the 
trachea, lungs, and air sacs due to the infiltration of heterophils and macrophages during early 
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infection, with lymphocytes (predominantly T cells) populating the lesions beginning around 5 
days post infection (316, 318).   
 M. gallisepticum was once determined by the United States Federal Government to be 
one of the top 3 most significant avian pathogens to U. S. poultry producers.  As a consequence 
of the rapid spread, chronicity of infection and significant economic impacts resulting from M. 
gallisepticum infection, it was including in the National Poultry Improvement Plan (NPIP) 
beginning in the 1960’s (NPIP05).  This plan served to provide guidelines to control the spread 
of the pathogen, and improve poultry and poultry products throughout the U. S.  Strategies 
currently used by commercial farms to reduce the spread and morbidity of this pathogen include 
strict biosecurity measures, antibiotic therapy, and vaccination programs.  However, medications 
and vaccines have not been able to eradicate the infection, especially in multi-age layer farms.  
Therefore, in severe cases, culling of entire flocks may be used to control the spread of infection 
(312, 319).   
 Further risk of spreading M. gallisepticum between backyard flocks is likely due to 
infection of turkeys and house finches.  Infection in turkeys results in sinusitis and conjunctivitis, 
and house finches present with conjunctivitis (313, 320).  Recently, the emergence of a new 
strain of M. gallisepticum was identified in house finch (Carpodacus mexicanus) populations in 
the eastern United States in 1994.  This strain causes severe conjunctivitis in house finches; 
however, it only results in mild disease when used to experimentally infect chickens (321).  M. 
gallisepticum has also been isolated from passerine birds including purple finches, blue jays, and 
American goldfinches which may contribute to the spread and morbidity (322).   
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Virulence Factors and Pathogenesis 
 
 A critical first step in M. gallisepticum pathogenesis is cytadhesion to the host’s mucosal 
epithelium as it prevents clearance by the host mechanisms such as ciliary action, and enables 
colonization of the respiratory tract (174, 197).  Cytadhesion is mediated by the primary adhesin 
molecule GapA, and the cytadhesion associated molecule CrmA (166).  These molecules are 
thought to be homologs of the P1 and B/C adhesin molecules of M. pneumoniae (164, 167).  
Once attached, pathological changes occur in the host cells including increased mucus 
production and release from goblet cells, ciliostasis and loss of cilia, and rounding and 
exfoliation of epithelial cells (323, 324).  Genomic sequencing of attenuated M. gallisepticum 
strains indicated that avirulent Rhigh lacks several genes compared to virulent Rlow including gapA 
and crmA (325).  To restore cytadherence and virulence to Rhigh, complementation with both 
gapA and crmA was necessary (166).  Transposon insertion mutations in Rlow gapA and crmA 
genes has also shown to reduce the cytadherence capabilities by approximately 75% which 
significantly reduces the virulence of this strain in the host, further indicating their importance as 
virulence factors (326).  Avirulent Rhigh was also found to lack two genes responsible for binding 
fibronectin; hlp3 and plpA (208, 325).   
 As seen in other mycoplasma species including M. mycoides ssp. mycoides, metabolic 
proteins have been linked to virulence (86, 87).  Dihydrolipoamide dehydrogenase (lpd) is part of 
the pyruvate dehydrogenase complex pathway that is responsible for ATP production during 
glycolysis. The lpd gene was shown to have an important role in M. gallisepticum virulence 
when disruption of this gene with a transposon insertion resulted in a significantly attenuated 
strain (327).  This strain resulted in minimal to no pathology in the host and was rarely recovered 
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2 weeks post infection (328, 329).  Due to the mutation, the organism was likely unable to 
produce sufficient ATP to provide energy for survival within the host (328). 
 A mycoplasma-specific lipoprotein named ‘MslA’, is an immunogenic lipoprotein that 
exhibits reduced expression in the live attenuated F strain vaccine.  Furthermore, Rlow showed 
attenuated virulence in experimentally infected chickens when this gene underwent transposon 
mutagenesis (330).  While its association with virulence is not fully understood, it has been 
hypothesized that MslA may bind TLRs resulting in the activation of NF-κB and subsequent 
production of pro-inflammatory cytokines and chemokines (330). 
 Sialidase activity has also been shown to play an important role in virulence.  Transposon 
mutagenesis of M. gallisepticum gene MGA_0329, a homolog of sialidase in M. pneumoniae, 
resulted in the loss of sialidase activity as well as decreased virulence in experimentally infected 
chickens.  This was characterized by less severe tracheal lesions and mucosal thickening, as well 
as reduced bacterial recovery (124).  Given that sialidase production was shown to positively 
correlate with virulence, it was surprising that complementation was able to restore sialidase 
activity but did not restore virulence (125).  While the exact role of sialidase in virulence remains 
unknown, it has been hypothesized that sialylation protects against the hydrolysis of glycosidic 
bonds on the host cell surface and prevents degradation of the host ECM.  Therefore, removal of 
sialic acid residues may expose host antigens and play a role in autoimmune complications 
(124).  However, given the inability of sialidase complementation to restore virulence, the 
relationship is likely more complex than originally thought.   
 As previously discussed, variable expression of vlhA genes may be associated with 
virulence as they are a significant component of host-pathogen interaction. However, changes in 
expression of vlhA genes early in the course of infection indicate that they do not play a role in 
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the evasion of host antibodies (302, 306).  It has been suggested, however, that the ability of 
VlhA products to bind red blood cells may contribute to the dissemination of the organism to 
other locations within the host (331). 
 
Mycoplasma gallisepticum Vaccines 
 
 Numerous attempts have been made to develop safe and efficacious vaccines to protect 
poultry from M. gallisepticum infection.  The two types of vaccines that are currently available 
are bacterins, which are inactivated suspensions of whole organisms, and live attenuated 
vaccines (LAV).  Bacterins initially showed promise as vaccinated birds showed reduced clinical 
signs and air sac lesions, reduced the decline in egg production, and prevented vertical 
transmission (332–337).  However, the reduction in bacterial load was only minimal (338), and 
the lesions, while less severe, remained present (339).  Additionally, bacterins only provided 
limited protection against virulent R strain challenge (332–337). Adjuvanted LAVs have been 
used for M. agalactiae, M. capricolum subsp capricolum,M. mycoides subsp mycoides large 
colony type, and M. hyopmeumoniae.  These vaccines have been shown to provide partial 
protective efficacy and reduction in the spread of disease (340, 341). 
 The live attenuated F strain vaccine was derived from a strain first identified in 1956 
(342).  Continued passage of this strain revealed that the F strain had potential efficacy as a 
vaccine candidate once it had been passaged between 200 and 250 times (343).  This vaccine 
elicits a strong serological response (344), though the antibody response is not as significant as 
that seen in vaccinated chickens challenged with virulent Rlow (343).  The F strain vaccine is 
protective without resulting in lesions (345–347), is capable of displacing virulent Rlow (348) 
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thereby decreasing the bacterial load, and likely accomplishes this by outcompeting the virulent 
strain (329).  Upon challenge with Rlow, F strain prevented the development of lesions and 
disease (264, 349, 350).  However, it was also shown that the F strain vaccine was not safe in all 
conditions.  Vaccination in turkeys and young chickens resulted in vertical transmission and 
severe lesions (343, 351), and was shown to be associated with a delay in the onset of egg 
production in layer chickens (346, 352).  Regardless, chickens vaccinated with F-strain still fared 
better than non-vaccinated birds. 
 A temperature sensitive mutant (ts-11) was created through chemical mutagenesis (353).  
The maximum growth temperature suitable for this mutant is 33ºC, and therefore is only able to 
colonize the upper respiratory tract.  Administration of this vaccine was shown to be safe in both 
chickens and turkeys and induced a protective response.  Egg production remained normal and 
minimal lesions were only observed in < 10% of animals (336, 337).  It has also shown to persist 
within the vaccinated host for several months with limited horizontal transmission (344, 354).  
However, further analysis revealed that protection varied likely due to the low antibody response 
(354–356).  Furthermore, while the ts-11 strain was able to displace the F strain, it was unable to 
displace virulent Rlow (357).  While this strain did not provide as much protection as the F strain 
vaccine, it was shown to be a safer option for young chickens and turkeys. 
 A third live attenuated vaccine, 6/85 was generated through serial passage in-vitro (344), 
and similar to the ts-11 vaccine, was shown to be safe in both chickens and turkeys and resulted 
in very few mild lesions (358).  The immune response upon challenge with a virulent strain was 
weak and varied between animals, and did not elicit any detectible serum antibodies (344, 358).  
Additionally, 6/85 was unable to displace or prevent the spread of virulent strains (359, 360).  
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While it has not been confirmed experimentally, reports of 6/85-like strains have been recovered 
in un-vaccinated animals (361, 362). 
 While the three commercially available vaccines have contributed to controlling M. 
gallisepticum, each have limitations. The F strain is protective but is virulent to young chickens 
and turkeys, both of which are typically in proximity to laying chickens.  Ts-11, a temperature 
sensitive mutant, is not able to displace virulent field strains in multiage facilities (311).  6/85, 
created through serial passage, only survives for a short period of time and results in very 
minimal serum antibody response (363). While both are safe, the host response to these vaccines 
varied and offered limited protection.  Therefore, further development of a vaccine that is safe 
for chickens and turkeys and capable of providing sufficient protection from virulent strains.   
 Two laboratory vaccine strains have been produced by The Center of Excellence for 
Vaccine Research (CEVR) at UConn to protect chickens from M. gallisepticum.  GT5, was 
created by complementing avirulent Rhigh with the cytadhesion gene gapA.  Complementation did 
not restore cytadhesion capabilities, but was still shown to prevent lesions due to Rlow infection 
upon challenge (364).  Additionally, the host produced high serum IgG antibodies as well as 
mycoplasma specific IgG and IgA secreting B cells in the trachea as early as day 4 post 
challenge.  This corresponded with CD4+ and CD8+ T cells and B cells arranged in organized 
follicles in the lamina propria unlike the disorganized infiltration of lymphocytes seen during 
natural infection (273). 
 The second attenuated vaccine strain, Mg 7, was created by transposon mutagenesis with 
an insertion in the metabolic gene dihydrolipoamide dehydrogenase (lpd) (328).  The lpd gene 
contributes to the production of ATP during glycolysis.  Analysis of this strain indicated limited 
colonizing capabilities as only 12.5% of samples contained Mg 7 two weeks post infection (328, 
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329).  Virulence was also limited resulting in minimal lesions in the trachea and air sacs, while 
the vaccine was still able to evoke antibody levels similar to those induced by virulent Rlow 
infection (329).  Analysis of GT5 and Mg7 indicated that they both outperformed commercially 
available vaccines; however, Mg 7 induced higher M. gallisepticum specific IgG serum 
antibodies than GT5, and also resulted in lower levels of post-challenge recovery of Rlow 
suggestive of prophylactic immunity (329). 
 Both laboratory attenuated vaccine strains passed the ‘proof-of-concept’ stage of 
development and were shown to outperform the F strain, ts-ll and 6-85 vaccine strains under 
laboratory controlled settings (329).  Unfortunately, GT5 and Mg 7 were created using 
transposon insertions that contain a gentamicin selectable marker, making them unsuitable for 
commercial production.  Therefore, there is still a need to develop a safe and efficacious vaccine 
with fewer limitations than those that are currently available.  Better understanding of the 
pathogenic mechanisms utilized by M. gallisepticum and the subsequent host response is 
necessary to guide the development of these future vaccines. 
 
Immune Response to M. gallisepticum 
 
 Infection of the chicken respiratory tract with M. gallisepticum at the mucosal epithelium 
results in the colonization of the trachea and development of lesions due to immune cell 
infiltrates into the lamina propria (318, 365).  Initial host-pathogen interaction is thought to 
largely occur between the lipoproteins anchored to the mycoplasma membrane with TLR-2 
(TLR-2/TLR-1 or TLR-2/TLR-6 heterodimers) on the epithelial cell surface.  As seen in in vivo 
analysis, this results in a robust pro-inflammatory response as indicated with an upregulation in 
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several chemokines and cytokines such as lymphotactin, CXCL-13, CXCL-14, RANTES, IL-6 
and MIP-1β between days 1 and 8 post infection (224).  In vitro exposure of cultured tracheal 
epithelial cells (TECs) and tracheal ex vivo exposure to M. gallisepticum revealed a similar yet 
transient upregulation of gene expression profiles at 1.5, 6, and 24 hours.  However, these studies 
have shown differences regarding the expression levels of CCL-20, IL-1β, IL-8, IL-12p40, and 
IFN-γ (170).  Furthermore, it has been suggested that insufficient levels of IL-12p40 and IFN- γ 
may result in the incomplete activation of macrophages during M. gallisepticum infection (366).   
 Early studies on the adaptive immune response to M. gallisepticum showed that chickens 
were more susceptible to infection upon bursectomy and thymectomy resulting in deficient B 
and T cell lymphocytes (367), and that IgG antibodies against M. gallisepticum inhibited 
cytadhesion to cultured tracheal rings ex vivo (368).  Analysis of lymphocyte infiltrates showed 
consistently increased levels of CD8+ T cells found between the upper and lower respiratory 
tracts.  CD4+ T cell levels outnumbered CD8+ T cells nearly 2 to 1, and were positively 
correlated with bacterial load (369).  As previously discussed, antibodies have been shown to be 
important mediators of protection in vaccinated chickens.  Chickens vaccinated with GT5 were 
found to have higher serum IgG as well has higher M. gallisepticum specific IgG and IgA 
secreting plasma cells in the trachea mucosa compared to unvaccinated chickens (273).  
Furthermore, CD8+ T cells were found to be the predominant cell type as early as 1-day post 
challenge, that were then surrounded by clusters of CD4+ T cells by day 4, with CD8 + T cells 
scattered throughout the lamina propria (273).  However, analysis using the ts-ll vaccine strain 
indicated an initial response dominated by CD8+ T cells that were gradually replaced by CD4+ T 
cells and was then predominated by B cells (369).  Therefore, these studies suggest that the role 
of T cells in the adaptive immune response to M. gallisepticum is still poorly understood.   
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 Despite the robust host immune response to M. gallisepticum, this organism is known for 
establishing chronicity and the development of significant respiratory disease in chickens.  
Studies to date have helped to elucidate the role of chemokines and cytokines as key players of 
the pro-inflammatory host response.  However, given the complex nature of the interaction 
between M. gallisepticum and the respiratory mucosa, further analyses are needed to better 
understand the molecular events that may contribute to the development of CRD. 
 
 
Significance, Hypotheses and Specific Aims 
 
 Previous studies have contributed significant data aiding in the understanding of the early 
pro-inflammatory response to M. gallisepticum.  However, a broader understanding of the 
complete tracheal host response is needed to identify key steps in the biological pathways that 
lead to a maladaptive versus beneficial immune response.  The analysis of both pathogenic and 
attenuated vaccine strains will indicated key differences between the host response and its ability 
to result in either immunopathogenesis or protective immunity.  Elucidation of these initial 
molecular events will indicate which host cell receptors, immune signaling pathways, cytokines 
and chemokines play important roles in the response to M. gallisepticum that may have 
previously gone unappreciated.  These components could then be targeted and differentially 
regulated through the development of vaccines to provide protection from wild-type, virulent 
strains, and induce long-term immunological memory. 
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Hypotheses: 
 
 Hypothesis 1: The host immune response will show broad changes in regulation of genes 
encoding proteins with immune function in response to pathogenic M. galliespticum strain Rlow. 
 Hypothesis 2: On days 1 and 2 post-infection, attenuated M. galliespticum strain Mg 7 
will evoke broad differential expression in metabolic and immune related genes comparable to 
the host response to virulent strain Rlow, whereas infection with attenuated strain GT5 will result 
in limited differential gene expression. 
 
Specific Aims: 
 
 Specific aim 1: Investigate and characterize the transcriptional profile of the tracheal host 
response to M. gallisepticum strain Rlow over a seven-day time course. 
 Specific aim 2: Investigate, characterize and compare the transcriptional profile of the 
tracheal host response to two attenuated vaccine strains, GT5 and Mg 7, to that of virulent Rlow 
on days 1 and 2 post-infection.   
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Abstract 
 
 Mycoplasma gallisepticum, the primary etiologic agent of Chronic Respiratory Disease 
(CRD) in poultry, leads to prolonged recruitment and activation of inflammatory cells in the 
respiratory mucosa. This is consistent with the current model of immune dysregulation that 
ostensibly allows the organism to evade clearance mechanisms and establish chronic infection. 
To date, studies using qRT-PCR and microarrays have shown a significant transient up-
regulation of cytokines and chemokines from tracheal epithelial cells (TECs) in vitro and 
tracheal tissue ex vivo in response to virulent strain Rlow, that contributes to the infiltration of 
inflammatory cells into the tracheal mucosa.  To expand upon these experiments, RNA was 
isolated from tracheas of 20 chickens infected with M. gallisepticum Rlow and 20 mock-infected 
animals at days 1, 3, 5 and 7 post inoculation, and analyzed for differential gene expression using 
Illumina RNA sequencing.  A rapid host response was observed 24 hours post-infection, with 
over 2,500 significantly differentially expressed genes on day 3, the peak of infection.  Many of 
these genes have immune related functions involved in signaling pathways including the TLR, 
MAPK, Jak-STAT, and the NOD-Like Receptor. Of interest, was the increased expression of 
numerous cell-surface receptors including TLR-4 and -15 which may contribute to the 
production of cytokines.  Metabolic pathways were also activated on days 1 and 3 post-infection, 
ostensibly due to epithelial cell distress that occurs upon infection. Early perturbations in tissue-
wide gene expression, as observed here, may underpin a profound immune dysregulation, setting 
the stage for disease manifestations characteristic of M. gallisepticum infection.   
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Introduction 
 
Mycoplasma gallisepticum is the primary etiologic agent of Chronic Respiratory Disease 
(CRD) in poultry.  Infection with this pathogen results in decreased feed efficiency, reduced 
weight gain, subsequent  downgrading of carcasses, and limited egg production and hatchability. 
Three commercial vaccines are available to control M. gallisepticum infection, however, further 
development of an improved vaccine that is safe and efficacious for susceptible birds of multiple 
ages and species is needed (1, 2).  To ensure eradication, broiler industries cull their entire flocks 
in the event of a sporadic outbreak. However, with M. gallisepticum infection frequently found 
in US egg-laying facilities, culling is not economically feasible (1-3).  These flocks often remain 
infected for life and provide the opportunity for further spread of infection to other facilities and 
wild birds (1,4).    
The host mounts a vigorous inflammatory response to M. gallisepticum resulting in 
respiratory distress in chickens (1).  Lesions of varying severity are found lining the trachea and 
air sacs due to colonization of the bacteria and the excessive recruitment and activation of 
inflammatory cells.  This is one aspect of the immune dysregulation orchestrated by M. 
gallisepticum that allows it to establish chronic infection (5-10). In addition, virulent strains of 
M. gallisepticum, such as Rlow, are able to avoid clearance by the host’s natural defense 
mechanisms of the respiratory tract by cytadhering to tracheal epithelial cells.  This is established 
by the function and co-expression of the primary cytadherence molecules GapA and CrmA that 
play a critical role in colonization and pathogenesis (11-13).  
Previous studies assessing the host tracheal response to M. gallisepticum have utilized 
methods such as exposure of cultured tracheal epithelial cells in vitro and whole trachea ex vivo 
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(9, 10, 14, 15). The most relevant to this current study, however, was an in vivo analysis of 
chemokine and cytokine expression profiles of the tracheal host response to Rlow (14). Over the 
course of an 8-day infection, increased expression of pro-inflammatory chemokines and 
cytokines including lymphotactin, CXCL13, -14, RANTES, IL-6 and IL-1β was observed, while 
decreased expression was seen in CCL20, IL-8, and IL-12p40. While ex vivo and in vitro studies 
have revealed similar expression profiles, some discrepancies exist regarding the significance 
and expression kinetics of inflammatory genes. Irrespective of these differences, these studies 
further support the premise that the overwhelming host response is ineffective at clearing the 
organism and contributory to the immunopathogenesis observed upon infection; thereby 
contributing to the development and progression of CRD (9, 10, 14).  
Studies to date have provided beneficial but limited insight into the host response to M. 
gallisepticum through methods such as qRT-PCR and microarrays. Given the potential 
interactions and downstream effects of the pro-inflammatory genes that have been implicated to 
date, we hypothesized that the tracheal host response will show much broader changes in 
differential expression than what has currently been identified. To expand on previous studies, 
we have utilized RNA Sequencing of the host tracheal tissues subsequent to infection with 
virulent M. gallisepticum strain Rlow over a seven-day time course.  This will provide a 
comprehensive, unbiased assessment of the changes in gene expression that comprise the 
maladaptive host response.  
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Results 
Global Differentially Expressed Genes (DEGs)Between Infected and Control Chickens  
  Sampling directly from the tracheal lumen yielded sufficient quantities of RNA to assess 
transcripts from each chicken and mapped to 17,935 Gallus gallus genes.  Day 1 post-infection 
contained 1,913 DEGs; 2,523 on day 3; 435 on day 5, and 351 on day 7. This indicated that the 
host mounts a rapid response to M. gallisepticum strain Rlow that peaked at day 3 and decreased 
towards baseline levels by day 7. Days 1 and 3 post-infection contained the largest number of 
unique DEGs likely due to the numerous metabolic pathways seen to be involved during early 
infection as indicated by pathway analysis (Fig. 1a, 2).  At each timepoint, the number of DEGs 
with increased expression values exceeded those with decreased expression (Fig. 1b).   
 
Pathway Analysis 
 The number of pathways affected by M. gallisepticum Rlow as identified by containing a 
minimum of two DEGs, was 117 on day 1; 126 on day 3; 51 on day 5, and 39 on day 7. Out of 
168 total metabolic pathways identified in chickens, days 1 and 3 post-infection indicated that 
there were 65 and 72 metabolic related pathways, respectively, containing DEGs (Fig. 2). As the 
course of infection continued, the number of metabolic pathways involved decreased to 18 on 
day 5 and 9 on day 7 reflecting a return toward homeostasis.  There were 46 pathways involving 
immune related functions categorized within immune signaling, signal transduction, and 
signaling molecules. Less variability was seen within immune-related pathway categories 
throughout the time course with 21 pathways identified as affected by infection on days 1 and 3, 
15 on day 5, and 18 on day 7. 
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Functional Gene Ontology (GO) 
 Functional ontology assessment of the DEGs allowed the genes to be categorized based 
on enriched biological processes (Fig. 3).  On day 1 post-infection, there were 195 genes with a 
log2 fold change ≥ 2.00.  While a large proportion of metabolic pathways were indicated on days 
1 and 3 post-infection (Fig. 2), very few differentially expressed metabolic genes had a log2 fold 
change ≥ 2.00 which resulted in a minimal number of metabolic genes being assessed.  The 
biological process with the highest percentage of genes per GO term was the ‘antimicrobial 
humoral response’ at nearly 43%. Of interest, was the number of associated DEGs found in 
biological processes related to the host immune, inflammatory and defense responses as well as 
‘immune cell migration’. 176 DEGs were categorized on day 3 post-infection and indicated 
additional mitogenic and cytokine-related cellular response as shown by the presence of the 
‘regulation of ERK1 and ERK2 cascade’, ‘response to interferon-gamma’ and the ‘cytokine-
mediated signaling pathway’ that were not seen on day 1. Day 5 post-infection categorized 165 
DEGs which included two unique biological processes; ‘phagocytosis’, and ‘antigen processing 
and presentation of exogenous antigen’ with the highest percentage of genes per GO term at 
43%.  There were 184 DEGs categorized on day 7 post-infection, and while there was still 
indication of the continued host response to the bacterial pathogen, there were many more 
processes related to the regulation of the immune response.  In addition, this was the first time 
that processes related to ‘T-cell selection and differentiation’ were identified, potentially 
reflecting antigen processing, cellular activation and proliferation/differentiation over time.   
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Immune Response 
 Due to the significant enrichment of immune genes further assessment of immune-related 
pathways was conducted.  Pathways including DEGs included, but were not limited to, cytokine- 
cytokine receptor interaction, the Toll-like receptor (TLR) pathway, the mitogen-activated 
protein kinase (MAPK) pathway, and the nucleotide oligomerization domain (NOD)-like 
receptor pathway (Fig. 4). Each of the aforementioned pathways are involved in pathogen 
recognition and the pro-inflammatory environment initiated by the production of chemokines 
and cytokines.  The number of DEGs per pathway increased from day 1 to day 3 (peak), 
decreased at day 5, and appeared to level out by day 7. The cytokine-cytokine receptor 
interaction pathway contained the greatest number of DEGs and these predominantly encoded 
cytokine receptors (Fig. 5).  
 As expected, TLR-2 and -1A showed significant differential expression on days 3 and 7 
post-infection (Fig. 6). Interestingly, TLR-4, traditionally a pattern recognition receptor (PRR) 
for lipopolysaccharide, a ligand that is absent from Mycoplasma species, was significantly 
increased at each time point.  TLR-15, unique to avian species, was also found to be significantly 
increased at all timepoints.   
   
Genes with Greatest Differential Expression  
 Fold change values for the top 25 genes per time point ranged from a log2 fold change 
value of -5.0 to +9.2 (Table 1). Protein functions encoded by these genes are involved in 
pathogen recognition, receptor ligation, pro-inflammatory cytokines and chemokines, catalytic 
activity, negative feedback of inflammation, as well as the maintenance and remodeling of tissue 
structure.  Of the 131 DEGs common to all four time points, many of the genes with the greatest 
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log2 fold change were involved with the host’s pro-inflammatory response, defense, and repair 
mechanisms including CCL5, TLR15, TLR4, IL-1b, IL-8, BPI and MMP9 (Table 2). The fold 
change of differential expression for many of the pro-inflammatory genes was transient and 
peaked at either day 3 or day 5 post-infection while the fold change of other genes was stable 
over the course of infection.  Importantly, the continued significant differential expression of 
multiple cell receptors, pro-inflammatory cytokines and chemokines, highlights the sustained 
signaling of immune-related pathways. 
 
Discussion 
 
 This study examined global transcriptomic analysis of differential gene expression in 
chicken tracheal cells following exposure to Mycoplasma gallisepticum Rlow over a seven day 
time course.   In keeping with prior studies, this analysis provided copious data re-affirming the 
vigorous pro-inflammatory response mounted in the chicken trachea subsequent to M. 
gallisepticum infection.  This response is ostensibly due to prolonged signaling through epithelial 
cell receptors resulting in increased production of cytokines and chemokines paired with tissue 
infiltration of inflammatory cells (7, 10, 14, 15).  Previous ex vivo analysis of host tracheal 
epithelial cells had suggested that the exaggerated influx of inflammatory cells into the 
respiratory lamina propria is likely dependent upon robust TLR-2 signaling that occurs as early 
as 1.5 hours post-exposure to M. gallisepticum (10). Furthermore, in vitro exposure of tracheal 
epithelial cells to Rlow resulted in a rapid response with increased expression of inflammatory 
genes CCL20, IL-8, IL-6, IL-12p40, NOS2, CXCL13, -14, MIP-1β and IL-1β within 24 hours of 
exposure (10). Previous in vivo analysis, however, indicated that CCL20, IL-8, IL-12p40 had 
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decreased expression upon infection with Rlow while minimal changes were seen with IL-1β over 
the course of 8 days (14). The findings of the current study differed from those of earlier in vitro 
and in vivo studies; TLR-2 was found to be increased, but not to the extent seen with TLR-4 or -
15.  CCL20 (MIP-3α) showed decreased expression however this was only found to be 
significant on day 5, while differential expression of IL-12p40 (IL-12B) was only observed on 
day 1.  IL-1β, IL-8L1 and IL-8L2 showed significantly increased expression at each timepoint, 
which differed from the findings of the previous in vivo study. Given the important pro-
inflammatory function of IL-1β and chemotactic properties of IL-8L1 and IL-8L2, significant 
increased expression was expected. Differences found between these studies is likely a reflection 
of the difference in experimental methodology and hence the cell types captured in the analysis. 
It should be pointed out that the sampling methods used here and post-collection analysis was 
quite different in that the latter study used whole tracheal tissues whereas the current study only 
sampled cells in the trachea by pipetting TRIzol through the lumen. Based on the gene 
expression profiles observed in the current study, it appears that heterophils and lymphocytes 
were likely present in the samples collected, however the extent of tissue penetration is 
unknown, and certain cell populations may have been excluded (e.g. cells trapped in the 
connective tissue of the lamina propria). However, this TRIzol method is quite relevant to the 
study of differential gene expression in that the recovered cells are in close contact with the 
pathogen.  
 While increased expression of TLRs may not be a direct reflection of ligand binding and 
subsequent signaling, it is of interest that the host response increases the sensitivity of the 
epithelial and immune cells involved through increased expression of receptors. TLR-15, 
specific to avian and reptilian lineages and largely expressed on the surface of heterophils, 
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macrophages and fibroblasts, shares approximately 30% identity with TLR-2 (16-18).  It has 
been suggested that TLR-15 is a broad spectrum TLR that recognizes heat-stable components of  
both gram negative and positive bacteria, CpG oligonucleotides, tripalmitoylated lipopeptide, 
and lipopolysaccharide (LPS) (17, 18). More recently, it has been shown to be activated in the 
presence of diacylated lipopeptide from Mycoplasma synoviae (19).  In the current study, TLR-
15 had an average log2 fold change of 4.71 throughout the course of the 7-day infection and may 
reflect the persistent presence of M. gallisepticum (data not shown). The stable differential 
expression of TLR-15 was greater than that observed for TLR-1A and -2, unlike what was seen 
in previous in vitro work with M. gallisepticum (10). Its importance with respect to M. 
gallisepticum pathogenesis, however,  remains uncertain.  The increase in differential expression 
of TLR-4, while partly due to increased numbers of immune cells, may also indicate increased 
cellular response to extrinsic signals. Though M. gallisepticum does not contain LPS, the 
hallmark TLR-4 ligand, other studies have shown TLR-4 signaling due to the presence of 
damage-associated molecular pattern molecules (DAMPs) such as heparin sulfate, fibrinogen, 
fibronectin or heat shock proteins 60 and 70 as a result of damaged extracellular matrix (ECM) 
or injured cells (20-23).  Associated with this may be the significantly increased differential 
expression of matrix metalloproteases (MMP) 7 and/or 9 found within the top 25 DEGs at every 
time point. On day 3, MMP7 had the greatest increase in differential expression of all genes with 
a log2 fold change value of 9.22. In mucosal epithelium, MMP7 has been shown to play an 
important role in the injury response with increased expression found in cells surrounding the 
site of injury (24).  Research on Equine chronic obstructive pulmonary disease (COPD), 
suggested that MMP9 may serve as a marker for ongoing tissue remodeling (25).  It has also 
been proposed that disproportionate expression of MMPs, likely a result of increased cytokine 
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production, coupled with deficient expression levels of tissue inhibitors of metalloproteinases 
(TIMPs) may result in excess ECM degradation (20, 26, 27). Components of the ECM may then 
ligate TLR-4 and result in signaling through MyD88 (16, 20-22).  In addition, increased 
expression of TLR-4 may provide greater accessibility of endogenous gram-negative bacteria to 
this receptor. Ligation of TLR-4 and -15 and subsequent increase of pro-inflammatory cytokines 
may contribute to and perpetuate the exaggerated and dysregulated host immune response.   
 Significant differential expression of many cytokine and chemokine receptors was also 
observed over the course of infection.  For example, on day 3, the peak of infection as indicated 
by gross and histological analysis (data not shown) and the point at which the highest number of 
DEGs were observed, the number of cytokine/chemokine receptor genes found to be 
differentially expressed outnumbered the cytokine genes by a 4 to 1 ratio. This may indicate that 
M. gallisepticum infection results in increased cell sensitivity to inflammatory agonists by virtue 
of up-regulating receptors for signaling molecules not present on mycoplasmas.  
 Pathway analysis showed that the greatest change in proportion of pathway categories 
occurred in those with metabolic function, with the number of immune related pathways 
remaining constant.  However, further analysis for GO revealed that the majority of DEGs with 
log2 fold change ≥ 2.00 were related to pathogen recognition and the subsequent host immune 
response.  A recent study assessing the changes in miRNA due to M. gallisepticum strain HS in 
the lung, identified numerous miRNAs with gene targets found in immune pathways. These 
included, but were not limited to, genes found within the MAPK, TLR, and Jak-STAT pathways 
(28).  While the RNA-seq data presented cannot explicitly show gene regulation changes in 
individual cells, analysis of miRNAs and their targets further supports the differential expression 
seen in the tracheal host response presented here.  
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 Collectively, these differential gene expression data observed in this study further 
revealed the complexity of the host response to M. gallisepticum, especially at early time points. 
It is easy to envisage how the myriad differentially expressed inflammatory, signaling and 
immune response genes could result in a profoundly dysregulated host response. Numerous 
genes were found to have significant differential expression over the course of infection, and 
while there were significantly fewer DEGs were observed on days 5 and 7 post-infection, many 
pro-inflammatory genes maintained their expression throughout the time course. Both PAMPs 
and DAMPs likely contributed to the ligation of receptors that may not have been activated 
based solely on the components of M. gallisepticum and subsequent downstream signaling. The 
presence of PAMPs and DAMPs coupled with the increased expression of PRRs and cytokine 
receptors, may underpin the robust host response that results in the recruitment and activation of 
inflammatory/immunoregulatory cells, thereby establishing an ecological niche favoring 
pathogen persistence. As previously mentioned, recruitment of various immune cells into the 
lamina propria during the course of M. gallesipticum infection. While the changing cell 
populations may also contribute to differences in expression observed here, it does not mitigate 
the potential importance of these changes in the local host response.  
This study has provided global assessment of the chicken tracheal response to M. 
gallisepticum over the course of early infection and further elucidated the complex response 
contributing to the early development of CRD. Better understanding of these molecular events is 
critical in identifying those which lead to a maladaptive rather than beneficial host response and 
may be important in the development of future therapeutics and vaccines.  
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Materials and Methods 
 
Animals 
 Four-week-old female specific-pathogen-free White Leghorn chickens (SPAFAS, North 
Franklin, CT, USA) were received and divided randomly into groups, placed in HEPA-filtered 
avian isolators, and allowed to acclimate for one week. Non-medicated feed and water were 
provided ad libitum throughout the experiment. All components of the study were performed in 
accordance with approved UConn IACUC protocol number A13-001. 
 
Chicken Infection 
 Stocks of M. gallisepticum strain Rlow (passage 17) were grown in Hayflick’s complete 
medium overnight at 37°C until mid-log phase was reached as indicated by a color shift from red 
to orange. Bacterial concentrations were determined by the OD620 and 10-fold serial dilutions 
were conducted to confirm viable color changing unit titers. Bacteria were pelleted by 
centrifugation at 10,000 x g for 10 minutes and resuspended at 5 x 108 CFU/ml in Hayflick’s 
complete medium. Chickens were challenged by pipetting 1 x 108 CFU/200 µl (‘infected’) or 
200 µl of Hayflick’s medium alone (‘control’) into the tracheal lumen as previously described 
(29). 
 
RNA Extraction 
 Five infected and five control chickens were humanely sacrificed each day for seven 
consecutive days. Tracheas were excised and total RNA was collected by pipetting 1 mL TRIzol 
reagent four times through the lumen of each individual trachea (30) to minimize the changes in 
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gene expression that may occur during the time between specimen collection and RNA 
purification (Invitrogen, Carlsbad, CA, USA). Total RNA was then purified using the Zymo-
Direct-zol RNA Miniprep Kit according to manufacturer’s instructions (Zymo Research 
Corperation, Irvine, CA, USA).  
 
Illumina Sequencing 
 cDNA libraries were created from RNA isolated from individual chickens on days 1, 3, 5, 
and 7 post-infection using the Illumina TruSeq Stranded mRNA Library Preparation Kit 
(Illumina Inc., San Diego, CA, USA) according to the Illumina TruSeq RNA Sample Preparation 
v2 (HT) protocol. Briefly, PolyA selection was performed using RNA purification beads on 0.1-
4 µg of total RNA per sample to obtain mRNA. 10-400ng of purified mRNA was fragmented 
and used to synthesize first-strand cDNA using reverse transcriptase and random hexamer 
primers.  Second-strand cDNA synthesis was performed using dNTPs including dUTP, DNA 
polymerase, and RNase. End repair was performed by adding dATP to all free 3’ ends and 
adaptor ligation added unique index sequences to the fragments.  The products were then 
amplified by PCR and purified. 
 The cDNA libraries were quantified using the Qubit 2.0 fluorometer (Invitrogen) and 
assessed for correct fragment size (~260bp) using the Agilent TapeStation 2200 (Agilent 
Technologies). Libraries were normalized to 2nM, pooled, denatured and sequenced on the 
NextSeq500 Sequencing platform (Illumina Inc.) using a 75bp paired-end approach targeting 
approximately 10 million reads per sample.  
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RNA-Seq Analysis 
Fastq data from individual birds were mapped using the TopHat package (version 2.0.1) 
utilizing the Bowtie2 engine (version 2.2.5) to align reads to the Gallus gallus reference genome 
(WASHUC2) producing BAM alignment files (31).  BAM files for each day were processed as 
experimental condition groups with Cufflinks (version 2.2.1) to assess aligned reads against 
reference transcripts using Cuffdiff to calculate treatment group-specific expression values and 
statistical significance of between-group differential expression. Within-condition normalization 
of data using Cuffdiff was achieved by calculating the fragments per kilobase of exon per million 
fragments mapped (FPKM) for each gene. The generated p-value was then used to determine the 
significance of the differential expression based on the Benjamini-Hochberg correction with a 
false discovery rate (FDR) of <5% to generate the q-value.  Between-condition differences in 
expression values were considered significant when q ≤ 0.05, thus addressing within-condition 
variation for all biological replicates on each day. Fold change was determined from the log2 
transformation of the ratio of FPKM between conditions (31, 32). For this study, all references to 
differentially expressed genes (DEGs) implies statistical significance.  The data discussed in this 
publication have been deposited in NCBI’s Gene Expression Omnibus and are accessible 
through GEO Series accession number GSE101403 
(htps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101403). 
 
Pathway Analysis 
Identification of biological pathways that significant DEGs were involved in, was 
performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
version 6.7 (33). Pathways containing ≥ 2 significant DEGs were categorized and displayed. 
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Functional Gene Ontology 
 DEGs with a log2 fold change ≥ 2.00, as identified by Cuffdiff, were analyzed to identify 
enriched biological processes based on Gene Ontology (GO).  This was performed using 
ClueGO v2.3.2, a plugin of the software platform Cytoscape v3.5.0-RC1 (34). Processes that had 
a p-value ≤ .05 for each time point were considered significant and displayed. 
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FIG 1 The number of DEGs between infected and control chickens per time point as identified 
by Cuffdiff. (a)Venn diagram displaying the total number of DEGs. Gray scale is based on the 
number and percentage of genes identified. (b) The number of DEGs with increased or decreased 
expression. 
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FIG 2 Pathway analysis. Pathways containing ≥ 2 DEGs were categorized based on function 
using DAVID Bioinformatics software. The number of identified pathways per category is 
indicated. 
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FIG 3 Functional Gene Ontology. Significant DEGs with a log2 fold change ≥ 2.00 were 
analyzed for enriched biological processes using the ClueGO application for Cytoscape. Bars 
represent the percentage of associated genes assigned to a unique GO term with the absolute 
number of associated genes located at the end of the bars. The color of the bars indicates 
functionally related groups based on the similarity of associated genes. Significance of enriched 
biological processes are as indicated (* = p £ 0.05, ** = p £ 0.001). 
 
 
 
FIG 4 Immune-related Pathways. Pathway analysis using DAVID Bioinformatics software 
identified the number of DEGs involved in immune-related pathways at each time point. 
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FIG 5 Cytokine-cytokine Receptor Interaction. DEGs identified on day 3 post-infection involved 
in this pathway are indicated with red stars as identified by DAVID Bioinformatics software. 
Green shading represents the completeness of the pathway identified within the Gallus gallus 
genome. 
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FIG 6 Toll-Like Receptors. TLRs identified by RNA-Seq are displayed. Differential expression 
of TLRs between infected and control birds is expressed as log2 fold change. Those with 
significant differential expression (q £ 0.05) are indicated (*). 
 
 
 
 
 
 
 
 
 
 106 
 
 
TABLE 1 Top 25 DEGs for each time point based on log2 fold change values as indicated by 
Cuffdiff.  
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TABLE 2 Top 30 DEGs Common to All Time Points. Sorted by Day 3 post-infection log2 fold 
change values as indicated by Cuffdiff. 
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Abstract 
 
Host immune responses to M. gallisepticum are complex, inducing increased expression 
of many pro-inflammatory chemokine and cytokine genes, and the influx of leukocytes into the 
mucosa, resulting in immunopathogenesis.  The need for improved vaccines that are both safe 
and efficacious in birds of different ages and species has driven the development of several 
laboratory attenuated vaccine strains.  As a first step toward understanding the attenuation 
process, we examined two well characterized strains generated in our laboratory; GT5 and Mg7, 
each of which were found to be protective upon challenge with virulent Rlow.  However, 
knowledge of the early molecular events that likely differ between the host response to virulent 
Rlow and attenuated vaccine strains GT5 and Mg7 is limited.  To elucidate these differences, we 
conducted an infection study comparing differential gene expression in tracheal tissues exposed 
to Rlow, GT5 and Mg7 on days 1 and 2 post-infection.  This enabled assessment of the early 
innate immune response that is critical in the development of disease and subsequent adaptive 
immunity.  Compared to the pronounced response to Rlow infection seen on day 1, GT5 and Mg7 
resulted in significantly fewer differentially expressed genes related to metabolic and immune 
functions.  On day 2, similar pathways were activated in Rlow and Mg7 exposed birds, while the 
genes involved in the response to GT5 exposure were less inflammatory, consisting primarily of 
genes associated with cellular growth and repair.  This study provides a greater understanding of 
maladaptive vs. beneficial host responses; information critical for the design of future vaccines 
efficacious in terms of both limiting inflammation and enabling clearance of the pathogen.  
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Significance 
 
 Current vaccines have reduced the incidence and spread of Mycoplasma gallisepticum in 
poultry, however, a safer and more efficacious vaccine is needed.  We conducted host 
transcriptional analysis to provide comprehensive understanding comparing early responses to 
virulent Rlow, and attenuated vaccine strains Mg7 and GT5. Differentially expressed genes 
(DEGs), both in number and magnitude of response were observed in cytokines and receptors as 
well as metabolism and other immune-related pathways.  Our data indicate several immune-
related genes and pathways affected by Rlow that are likely important in inducing adaptive 
immunity, but should resemble the response evoked by attenuated strains. Future vaccines should 
target genes common to virulent and avirulent strains to activate the appropriate host response, 
promote protective immunity and avoid immunopathogenesis. 
 
Introduction 
 
 Mycoplasma gallisepticum, an infectious respiratory pathogen, contributes to the 
development of Chronic Respiratory Disease (CRD) in poultry.  CRD in chickens is frequently 
associated with clinical signs including coughing, nasal discharge, and tracheal rales (1).  
Inflammatory lesions are most commonly found in the trachea, air sacs, lungs, and occasionally 
in the conjunctiva and oviduct (2).  Despite efforts to control outbreaks, M. gallisepticum results 
in significant worldwide economic losses due to decreased feed conversion efficiency, 
downgrading of carcasses, and reduced egg production and hatchability (1, 3).   
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Virulent strains of M. gallisepticum, such as Rlow, avoid clearance by the host’s 
respiratory defense mechanisms by initially cytadhering to tracheal epithelial cells and 
subsequently colonizing the mucosal surface.  Tight attachment is mediated by an ‘attachment 
organelle’ comprising the cytadherence molecules GapA and CrmA, which are required for 
colonization and pathogenesis (4).  Disruption of either of these genes results in limited 
colonization and a dramatically reduced host response and its associated pathology (4–6). 
The tracheal host response to Rlow is characterized by a marked influx of inflammatory 
cells into the lamina propria (7, 8) and is associated with robust signaling of Toll-like receptors 
(TLRs) in epithelial cells lining the tracheal lumen (9). This results in increased expression of 
pro-inflammatory chemokines and cytokines including IL-6, IL-8, CCL20, CXCL-13, -14, and 
RANTES that are likely sustained due to increased signaling and activation of  immune cells  
associated with Rlow colonization (8–10).  Over time, thevigorous host response is associated 
with a dramatic reduction in bacterial load, however, it is incapable of clearing the infection and 
the conconmitant immunopathogenic sequelae pre-dispose birds to co-infection and the 
development and progression of CRD (11–13).  
 Three widely used live attenuated M. gallisepticum vaccines are known as ‘F strain’, 
6/85, and ts-11. While highly effective, each of these vaccines have limitations that render them 
unsuitable in certain situations. For example, the F strain vaccine persists for the life of the 
chicken and is protective against virulent strains, however, it is pathogenic in turkeys and young 
chickens (14).  Vaccine strains ts-ll, a temperature sensitive mutant, and 6/85, which was 
geneated by serial passage, are non-pathogenic in chickens and turkeys, and are protective upon 
challenge, though protection levels and duration of immunity vary.  These vaccines are less 
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effective at displacing virulent strains, and 6/85 elicits little or no humoral antibody response 
(15–17).   
 Efforts to develop more efficacious vaccines have resulted in laboratory attenuated 
vaccine strains including GT5 and Mg7.   GT5 was created by complementing avirulent, high 
passage, strain Rhigh with wild-type gapA (4). GT5 induces lower levels of pro-inflammatory 
cytokines and chemokines compared to Rlow, and is capable of inducing the local recruitment of 
CD4+ and CD8+ T cells, B cells, and ultimately the production of M. gallisepticum specific IgG, 
IgA, and IgM antibodies ( 8, 18-20). Due to the number and magnitude of gene mutations in 
Rhigh and the modest immune response, incomplete clearance of organisms and less durable 
immunity, we consider this vaccine to be highly attenuated. Conversely, Mg7 is an Rlow isogenic 
mutant with a transposon insertional disruption  in the dihydrolipoamide dehydrogenase (lpd) 
gene (21). As such, Mg7 is genetically identical to the fully virulent R low strain but lacks a single 
metabolic gene, and hence is considered only mildly attenuated. Virulence assessments of Mg7 
indicated limited colonization capabilities and minimal lesions in the trachea and air sacs, while 
still evoking  levels of antibodies consistent with  other vaccines (20, 21).  Comparing the 
efficacy of these two live-attenuated vaccines indicated that chickens could rapidly clear the 
challenge strain (Rlow) and had significantly reduced histopathologic lesion scores (20).  Both 
GT5 and Mg7 outperformed the commercially available vaccines in laboratory controlled 
studies. Mg7 resulted in significantly lower levels of post-challenge recovery of Rlow suggestive 
of, and highly correlated with, prophylactic immunity (20).  While GT5 and Mg7 have been 
shown to be protective without resulting in significant immunopathology in a laboratory setting, 
further understanding of the host response to these strains is needed to determine which elements 
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of the host response are required to induce protective immunity versus those which are 
potentially maladaptive.  
  Previous transcriptional analysis conducted in our laboratory yielded a global assessment 
of the chicken tracheal response to Rlow over the course of a 7-day infection.  This expanded our 
knowledge of the immunological pathways involved, and highlighted the changes in cellular 
metabolism, stress, and cellular injury that occured during virulent M. gallisepticum infection, 
some of which may contribute to the exagerated host response (10).  Based on the rapid host 
response that peaked in both gene expression and tracheal thickness during early infection with 
Rlow, the current study aimed to compare the differences between the host response to virulent 
Rlow and attenuated strains GT5 and Mg7 during these early time points.  Comparison of the 
intitial molecular events that occur in the respiratory mucosa upon initial infection is imperative 
as pathway activation and production of cytokines and chemokines set the trajectory for the 
magnatude of inflammation and disease related changes, and contribute to the induction of the 
adaptive immune response resulting in protective immunity.  Assessing early infecition, prior to 
significant immune cell infiltrates observed at day 3, will provide a more accurate representation 
of the epithelial cell response. To accomplish this, we conducted a 2-day infection study 
followed by RNA sequencing to assess the transcriptional changes occurring in host genes that 
may help identify key steps in pathways leading to either a maladaptive or beneficial immune 
response to M. gallisepticum.  This knowledge may provide a framework to guide the 
development of attenuated vaccines.  Future tailored vaccines should retain specific elements of 
immune activation absent perturbation of genes associated with inflammation or 
recruitment/activation of cells not contributory to adaptive immunity.  
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Results 
 
Differentially Expressed Genes (DEGs) Between Control and Virulent or Attenuated Strains 
 RNA collected from cells lining the tracheal lumen of each chicken yielded transcripts 
that mapped to 17,935 genes within the Gallus gallus genome.  On day 1 post-infection there 
were  1824 differentially expressed genes (DEGs) observed in response to Rlow infection, 631 
DEGs due to Mg7 exposure,  and 257 due to GT5.  Approximately 60% of these DEGs showed 
increased expression in each group.  Day 2 post-infection resulted in a greater numbers of DEGs 
for each infection group; 2967 in Rlow with 57% increased, 1969 in Mg7 with 63% increased, and 
425 in GT5 with 74% increased (Fig. 1a, b).  Of the total DEGs, only 171 were common to all 
three infection groups on day 1, with 274 in common on day 2 (Fig. 1c).  As expected, the 
greatest number of unique DEGs were found in the Rlow infected group on both days. 
 
Pathway Analysis 
 Infection with M. gallisepticum strain Rlow resulted in the greatest number of affected 
pathways on both days; with 110 observed on day 1 and 134 on day two. Exposure to Mg7 
resulted in 69 pathways affected on day 1 and 115 on day 2, and GT5 exposure affected the 
fewest pathways with 35 on day 1 and 41 on day 2 (Fig. 2 a, c). The greatest number of activated 
pathways and DEGs were found within the ‘metabolism’ category on both days for each strain 
(Fig. 2 a-d).  The pathways affected by Mg7 followed a similar trend as the Rlow infected group, 
however, there were fewer pathways and DEGs observed within these pathway categories. The 
difference in DEGs between Rlow and Mg7 infection was especially notable within metabolism-
related pathways and those with immune related functions including ‘signal transduction’, 
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‘immune signaling’, and ‘signaling molecules’ (Fig. 2 b, d).  GT5 exposure affected the fewest 
number of pathways in both metabolic and immune related categories, and showed the least 
variability between time points.   
 
Functional Gene Ontology (GO) 
 Functional gene ontology assessment of the DEGs with a log2 fold change ≥ 2.00 enabled 
comparison of enriched biological processes identified in each infection group (Fig. S1).  On day 
1, there were 245 DEGs with a log2 fold change ≥ 2.00 due to Rlow infection, 79 DEGs due to 
Mg7, and 24 for GT5.  In keeping with our previous study (10), Rlow infection affected numerous 
biological processes involving host immune, inflammatory, and defense responses involved in 
pathogen recognition, cytokine and chemokine production, and chemotaxis.  The processes 
identified as a result of Mg7 exposure included similar cell responses such as chemotaxis and 
leukocyte migration, but appeared to be less broad as reflected by far fewer processes being 
affected.  GT5 exposure resulted in the fewest biological processes being affected.  On day 2, the 
number of DEGs assessed for each infection group were as follows; 194 in the Rlow group, 123 in 
Mg7 and 125 in GT5.  Many of the biological processes affected in the Rlow infected group on 
day 1 were also affected on day 2. One notable difference however, was the presence of ‘positive 
regulation of NF-kappaB import into nucleus’.  Mg7 exposure affected fewer processes than 
those observed upon  Rlow infection on day 1, however, these differences decreased by day 2.  
Notable differences included the presence of ‘cellular response to interferon-gamma’ only being 
indicated in the Rlow infected group, and the presence of ‘positive regulation of interleukin-6 
production’, ‘positive regulation of interleukin-8 production’, ‘macrophage activation’, and 
‘positive regulation of T-cell activation’ indicated in the Mg7 exposed group.  The greatest 
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difference between days 1 and 2 was seen in the GT5 exposed group with only 5 processes 
affected on day 1 and 64 processes affected on day 2.  The ‘leukocyte chemotaxis’ and 
‘neutrophil chemotaxis’ processes were not observed on day 2, nor were there any processes 
involved in the recognition of a bacterial pathogen or the host immune response.  The majority of 
additional processes that were identified in the GT5 exposed group included those involved in 
cell growth, repair, development, differentiation, and cell proliferation. 
 
Immune Pathways 
 Pathways of interest based on the differences in the host immune response to virulent and 
attenuated strains, included cytokine-cytokine receptor interaction, the mitogen-activated protein 
kinase (MAPK) signaling pathway, the nucleotide oligomerization domain (NOD)-like receptor 
pathway, the Janus kinase- signal transducers and activators of transcription (Jak-STAT) 
pathway, and the Toll-like receptor (TLR) pathway.  As expected based on the total number of 
DEGs found in each infection group (Fig. 1), the Rlow infected group contained the most DEGs in 
each of these pathways at both time points, and GT5 exposure resulted in a limited number of 
DEGs.  On day 1, the NOD-like receptor pathway indicated that Rlow infection uniquely affected 
pro-inflammatory genes including IL-6, RANTES and CASP1, while GT5 exposure did not 
affect any genes in this pathway.  On day 2, the cytokine-cytokine receptor interaction pathway 
indicated that Rlow infection affected IL-6, IL-12, TNFSF11, and approximately 24% more 
receptors than Mg7 (Fig. 3).  The differences in the MAPK pathway (not shown) included DEGs 
such as PKC, FAS, HSP72 and CASP that were only differentially expressed in the Rlow 
infection group, and TGF-β was only affected as a result of GT5 exposure.  Few differences were 
observed in the Jak-STAT pathway (Fig. 3); however, only Rlow infection affected the signal 
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transduction adapter molecule (STAM).  These molecules become activated upon stimulation of 
the Jak-STAT pathway due to cytokines and growth factors, and are involved in intracellular 
signal transduction (22, 23). In the TLR pathway, the most prominent differences between Rlow 
infection and Mg7 exposure were seen in the toll-like receptors and the down-stream products of 
the pathway including both inflammatory cytokines and costimulatory molecules.  IL-6, IL-12 
and CD40 were only affected in Rlow infection; IL-1β, RANTES, and CD80 were affected in Rlow 
infection and Mg7 exposure; and IL-8 was affected in all three groups (Fig. 3).  The greatest fold 
changes were seen in TLR-4 and -15 upon Rlow infection and were also significant in Mg7 
exposed chickens (Fig. 4). While there were more TLRs found to be significantly altered due to 
Rlow infection and Mg7 exposure on day 1, Mg7 exposure only resulted in significant differential 
expression of TLR-4 and TLR-15 on day 2.  The only TLR significantly affected by GT5 was 
TLR-21 on day 2. 
 
Genes with Greatest Differential Expression 
 To compare the host response to each strain, the top 30 common DEGs were determined 
and ranked based on the log2 fold change values of the Rlow infected group (Table 1).  Many of 
the common DEGs encode proteins with immune-related functions such as IL-13RA2, IL-1β, 
LYG2, IL-4I1, IL-20RA, IL-8L2, and BPI.  However, a greater proportion of these genes are 
related to functions including injury response, metabolism, cell adhesion and remodeling, 
extracellular matrix (ECM) degradation, and membrane transport.  Assessing the top DEGs due 
to GT5 exposure revealed that by day 2, most of the genes were involved in cell 
growth/proliferation, wound repair, and maintenance of the ECM (Fig. S2).  Therefore, to 
provide a more focused examination of specific differences in the host immune response, the top 
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30 DEGs unique to Rlow infection and Mg7 exposure (not found in GT5) were determined (Fig. 
S3).  Several DEGs potentially involved in the host’s pro-inflammatory response include TLR-4, 
-15, IL-1β, IL-1R2, IL-8L1, IL-22RA2, CXCL1, CCLI10, IRG1.  On day 1, Rlow infection 
resulted in greater differential expression than Mg7 exposure, whereas on day 2 the extent of 
differential expression observed in these two groups were less pronounced.  Lastly, to deduce 
differences in the host response to Rlow, the DEGs unique to Rlow infection were assessed (Fig. 
S4). DEGs with immune related functions included IL-6, IL-12B, IL-22, CCL4, CD80, 
CSF2RA, TNFSF11, and NCF2. 
 
Discussion   
 
 The development of attenuated vaccine strains derived from pathogenic bacteria has 
traditionally been performed randomly (e.g. serial passage, chemical/UV mutagenesis or by 
generating transposon mutant libraries), with subsequent assessments consisting of immune 
response, histopathology and protection studies. These time-honored yet inefficient approaches 
may give way to ‘precision’ vaccine design in which host responses are specifically tailored to 
match correlates of immune protection on a gene/pathway-specific basis, especially as we enter 
the age of CRISPR/Cas9 gene editing of synthetic bacterial genomes.  
As a first step, we must learn what current attenuated vaccines have in common, and 
more importantly, how they differ with respect to host responses to pathogenic strains. In this 
regard, the current study examined the global transcriptional differences in the host response to 
virulent versus attenuated vaccine strains of M. gallisepticum during early stages of infection.  
Previous studies have largely assessed the efficacy and adaptive host immune response to GT5 
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and Mg7 (8, 20, 21, 24), with only one study assessing the innate immune response to GT5 (19). 
These studies concluded that GT5 and Mg7 are non-pathogenic as they result in minimal 
inflammatory cell infiltration into the lamina propria and nominal increases in tracheal thickness. 
Both attenuated strains provide protection against virulent Rlow; interfollicular zones of CD4+ 
and CD8+ T cells were found in GT5 vaccinated birds upon challenge (8), and both GT5 and 
Mg7 resulted in IgG- and IgA- secreting plasma cells in tracheal tissue, and anti-M. 
gallisepticum IgG in serum (8, 20).  Comparatively, Mg7 resulted in greater tracheal thickness 
than GT5 likely due to a more robust cellular infiltration, however, it outperformed GT5 in 
protection as indicated by less pathology and lower rates of Rlow recovery 4 weeks after 
challenge (20).   
Differential expression of chemokines and cytokines were previously compared between 
Rlow infected and GT5 exposed chickens on days 1, 4 and 8 post-infection (19).  Notable findings 
of that study included decreased expression of CCL20, IL-8 and IL-12p40 in both GT5 and Rlow 
infected chickens 1day post-infection. Day 4 post-infection showed decreased expression of 
CCL20 and IL-12p40 in both GT5 exposure and Rlow infection, and GT5 exposure continued to 
show decreased IL-8 expression while Rlow infection was comparable to controls.  In the current 
study, expression of CCL20 was also found to be decreased in both Rlow infected and GT5 
exposed chickens on days 1 and 2. Conversely,  expression of IL-12B (IL-12p40) and IL-8 was 
increased, though not significant, on day 1 due to GT5 infection and was significantly increased 
as a result of Rlow infection.  Day 2 yielded significant expression of IL-8 as a result of both Mg7 
exposure and Rlow infection, and IL-12B as a result of Rlow infection.  It is important to note that 
our previous transcriptomic 7-day Rlow infection study utilizing RNA sequencing showed 
comparable results for these genes on days 1 and 3 post infection except for IL-12B which was 
 120 
only significantly increased on day 1 (10).  The current study used a different study design; 
performing a single inoculation with a dosage equal to or less than those in the previous studies 
(8, 19–21, 24), and sampling cells from the trachea by pipetting TRIzol through the lumen. In 
comparison, this approach may have resulted in a limited host response that peaked at an earlier 
time point, and may have only captured epithelial cells and cells loosely associated with the 
lamina propria.  However, these cells are most likely to be in close contact with the organism and 
hence more likely to differentially express genes in response to infection.   
 The significant number of DEGs found within metabolic pathways is ostensibly due to 
the epithelial cell distress that occurs upon infection (25); suggesting that Rlow infection results in 
greater cell stress and subsequent injury.  Cell stress is also known to trigger an immune 
response through activation of the inflammasome within the NOD-like receptor pathway (26, 
27). While activation of inflammasomes during host defense typically occurs in macrophages 
(26), the Nlrp3-inflammasome can be activated in murine respiratory epithelium during induced 
airway inflammation (28), and in human lung epithelial cells in the presence of silica (29).  
Additionally, recent studies have shown that other Mycoplasmas including M. salivarium (30), 
M. hominis (31), and the CARDS toxin of M. pneumoniae (32), are involved in the activation of 
inflammasomes.  Caspase-1, a regulator of the processing and secretion of interleukins IL-1β, IL-
18, and IL-22, a component of the Nlrp3-inflammasome, requires the presence and binding of 
extracellular ATP to the P2X7 purinergic receptor to become activated. Cellular efflux of ATP is 
known to occur during cellular stress and as a consequence of bacterial infections including 
Mycoplasma pneumoniae and M. hominis (33–36).  Additionally, it has been shown that the 
presence of TLR ligands, such as bacterial lipoproteins, are required to prime the cells to activate 
caspase-1 in response to ATP (26, 37). In the current study, we note that many of these genes 
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were indeed differentially expressed. For example, expression of the P2X7 receptor gene was 
significantly increased on Days 1 and 2 in both Rlow and Mg7 exposed chickens, with higher 
expression seen in the Rlow infected group (Fig. S5).  TLR-2, a well-characterized receptor for M. 
gallisepticum lipoproteins (9), was differentially expressed in all three infection groups on both 
days, however it was only statistically significant in the Rlow infected group (Fig. 4). CASP1 
showed increased expression in Rlow and Mg7 on both days, with higher levels in Rlow infected 
chickens which was significant on day 1. In the GT5 exposed group, CASP1 expression was 
minimally increased on day one, and actually decrease on day 2 in comparison to controls (Fig. 
S5).  Significantly increased expression of IL-1β was found on both days in response to  Rlow 
infection and Mg7 exposure, with the greatest differences found in the Rlow infected group.  In 
GT5 exposed chickens, IL-1β was only significantly expressed on day 1 (Table 1).  In the current 
study, we were unable to determine which cell type(s) the observed differential expression was 
attributed to, and it is unknown whether sufficient extracellular ATP was present. However, 
given the capabilities of other Mycoplasmas to activate inflammasomes and the expression 
profiles seen here, further study on the potential role of Nlrp3-inflammasomes in the 
pathogenesis of Rlow is warranted. 
Comparing gene ontologies between infection groups further supported the differences 
between virulent and attenuated vaccine strains.  The most prominent observation was the 
number of functional processes that are affected by Rlow on day 1 compared to those of the 
attenuated strains. While it has been well established that the host response to Rlow is rapid (8, 9), 
its magnitude was further highlighted when comparing it to the limited number of mitogenic and 
cytokine related host response processes activated upon Mg7 and GT5 exposures.   However, it 
is important to note that host cells responded to the presence of GT5 as indicated by the affected 
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chemotactic processes despite the limited cytadherence capabilities of this attenuated strain.  On 
day 2, the presence of ‘positive regulation of NF-kappaB import into the nucleus’ likely 
represents the expression and possible ligation of TLRs acting as ‘master switches’ are 
responsible for transcription of many downstream immune related genes.  The processes affected 
by Mg7 more closely resembled those seen in Rlow, indicating a more gradual activation of the 
host response.  GT5 exposure on day 2 affected processes primarily involved in repair and 
regrowth with only 2 processes involved in the pro-inflammatory host response.  The difference 
in the processes observed in the Rlow infected, and Mg7 exposed groups compared to the GT5 
exposed group may be due to its diminished cytadhesion capabilities, thereby reducing its 
attachment and residence time in association with the host mucosal epithelium.   
An interesting difference seen in the gene ontology of Mg7 exposed chickens on day 2 
was the ‘macrophage activation’ process.  The ability of Rlow to recruit macrophages has been 
established in previous in vivo and ex vivo studies, however, the extent to which they become 
activated is unknown based on conflicting data regarding IL-12p40 (IL-12B) and IFN-γ typically 
produced by activated macrophages, and may be yet another indicator of the dysregulated host 
response (19, 38).  It should be noted that the expression of IL-12B does not necessarily indicate 
the presence of activated macrophages; this cytokine can also be produced by dendritic cells and 
respiratory epithelial cells (9, 39). In the current study, expression of IL-12B was significantly 
increased on both days in the Rlow infected group, but varied greatly within Mg7 and GT5 
exposed groups and was not found to be significant.  Additionally, IFN-γ gene expression was 
not found to be significantly differentially regulated in any of the infection groups.  Whether the 
‘macrophage activation’ process indicated by gene ontology would result in activated 
macrophages, or whether the sampling method used in the study prevented accurate measures of 
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macrophage produced cytokines is unknown.  However, it would be beneficial to determine 
whether these attenuated vaccine strains are capable of activating macrophages that enable 
successful antigen presentation, as this would be a desirable trait in future vaccines.   
In addition to IL-12B, genes encoding proteins with immune related functions including 
IL-6, IL-22, and CCL4 (MIP-1β), were uniquely upregulated in Rlow infected chickens.  IL-6 is a 
multifunctional cytokine that has been shown to play a role in both host protection and disease 
exacerbation depending on which other cytokines are present (40–42).  Therefore, whether this 
cytokine is a contributing factor in the pathogenesis that results from Rlow infection remains 
unclear.  IL-22 is a pro-inflammatory cytokine produced by immune cells including Th17 
lymphocytes, acts on epithelial cells and requires tight regulation (reviewed in 37).  Similar to 
IL-6, this cytokine can contribute to maladaptive host immune responses depending on the 
presence of other pro-inflammatory cytokines, and may also result in increased levels of IL-6 
and IL-8 (reviewed in 37).  This may explain the unique expression of IL-6 and the greater 
expression levels of IL-8 in Rlow infected chickens compared to Mg7 and GT5 exposures.  CCL4 
is a chemoattractant for immune cells such as NK cells and monocytes (44), and may further 
contribute to the immune cell infiltrates and immunopathology of Rlow.  
Given the importance that TLRs have shown in Mycoplasma infections (9, 45, 46), it is 
important to consider the differences in expression of TLRs between virulent and attenuated 
strains.  Based on ex vivo analysis, it has been suggested that TLR-2 signaling in tracheal 
epithelial cells contributes to the notable influx of inflammatory cells into the lamina propria 
during Rlow infection (9).  In the current study, TLR-2 expression was only significantly 
increased in the Rlow infected chickens.  As seen in our previous Rlow infection study (10), TLR-4 
and TLR-15 were significantly increased on both days in Rlow infected chickens. Mg7 exposure 
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resulted in increased expression of these TLRs, but was still significantly lower than the 
expression seen in response to Rlow; GT5 exposure resulted in an equivocal increase in the 
expression of TLR-4 and -15. As previously discussed, increased expression of TLR-4 may 
indicate increased cellular response to extrinsic factors including the presence of damage-
associated molecular pattern molecules (DAMPs) such as heat shock proteins, heparin, 
fibrinogen and fibronectin as a result of damaged extracellular matrix (ECM) or cellular injury 
(10, 47–52).  Aside from cell stress related-injury, damage to cells and the ECM may be due to a 
disproportionate increase in the expression of matrix metalloproteases (MMPs) 7 and/or 9.  
These MMPs have been shown to play important roles during cellular injury and repair (47, 48), 
but also result in excess degradation of the ECM when increased cytokine production is coupled 
with deficient expression levels of tissue inhibitors of metalloproteinases (TIMPs) (49, 50, 53). 
Our studies have confirmed the observed perturbations in MMP7 and/or -9 expression, with 
significant increases in response to Rlow infection at all time points (10); in the current study an 
increase in expression of these MMPs was observed in response to both Mg7 and GT5 exposure.  
The greatest difference was seen in response to Rlow infection, but these genes were also 
expressed at higher levels in response to Mg7 infection, with the lowest levels seen in GT5 (10).  
TLR-15, which is unique to avian and reptilian lineages, is a broad spectrum TLR that 
recognizes lipopolysaccharide (LPS), CpG oligonucleotides, gram-negative and gram-positive 
bacteria, tripalmitoylated lipopeptide as well as diacylated lipopeptide from Mycoplasma 
synoviae (54–57).  The expression patterns of TLR-15 seen in each infection group was similar 
to that of TLR-4, and was significantly increased in Rlow infection throughout our previous 7-day 
time course (10).  Therefore, it is possible that the interaction of lipoproteins and the greater 
levels of cellular stress and damage due to Rlow infection, collectively contributes to the 
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increased expression of TLRs 2, 4, and 15, which in turn promotes disease exacerbation through 
the subsequent increased expression of pro-inflammatory cytokines and chemokines that are not 
expressed at the same magnitude in attenuated vaccine strains.    
Lastly, Rlow infection resulted in significant differential expression of many cytokine and 
chemokine receptors (Fig. 4). On day 1, the number of differentially expressed receptors was 
approximately 60% greater than that observed upon Mg7 exposure, and approximately 24% 
greater on day 2. GT5 exposure resulted in only one differentially expressed receptor on day 1 
and 2 receptors on day 2.  Taken together, wide-spread increases in expression of cytokine, 
chemokine,  and TLR receptors, may indicate that Rlow infection results in increased cell 
sensitivity to signaling molecules including host factors (e.g. cytokines/chemokines and their 
receptors) and those present on mycoplasmas, DAMPs, and endogenous gram-negative bacteria.  
The fact that GT5 exposure does not appear to induce increased sensitivity of host cells is 
significant and is consistent with the lack of immunopathology observed in response to this 
strain.  
Overall, based on the gene expression profiles observed in this study, it appears that the 
differences in host response to virulent M. gallisepticum strain Rlow compared to avirulent strains 
Mg7 and GT5 is partly due to the complex interplay between metabolism, cellular stress/injury 
and the subsequent pro-inflammatory response, and a possible increase in cellular sensitivity due 
to increases in gene expression of immune recognition receptors.  The host response to Mg7 
involves far fewer metabolic genes which suggests reduced cellular stress and damage, and 
evokes a proinflammatory response that is less robust and slower to evolve than that observed in 
response to Rlow infection.  GT5 evokes a response that is markedly dampened compared to both 
Rlow infection and Mg7 exposure; not only was the response on day 1 minimal in comparison, it 
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was the only strain that did not result in a significant increase in metabolic and immune related 
functions.  This may explain why previous studies showed that Mg7 out-performed GT5 upon 
Rlow challenge (20).  As previously mentioned, recruitment of various immune cells into the 
lamina propria due to M. gallisepticum infection varies between virulent strain Rlow and 
attenuated vaccine strains Mg7 and GT5.  Examining the differences of the host response to 
these strains during early time points has allowed comparison of the host’s initial interaction with 
M. gallisepticum, and was intended to assess whole tissue gene expression prior to the influx of 
immune cells into the lamina propria due to prolonged chemotaxis and activation of leukocytes 
observed in response to Rlow infection.  It is possible that the decreased response seen in Mg7 is 
partly due to its reduced metabolic abilities and limited viability, however it was shown that 
recovery of Mg7, though limited, occurred 2 weeks post-infection (21).  It is also assumed that 
differences seen in GT5 may in part be due to its limited cytadherence capabilities, resulting in 
reduced contact/residence in association with the host’s mucosal epithelium.   
Global transcriptional comparison of the early chicken tracheal response to virulent and 
attenuated vaccine strains of M. gallisepticum has illustrated the varied molecular events in 
metabolic and immune related pathways of potentially maladaptive vs. protective host responses.  
Development of future vaccines should aim to promote the expression of those immune-related 
genes expressed as a result of both Mg7 and GT5 infection, limit the magnitude of expression of 
those genes common to Rlow and Mg7, while avoiding proinflammatory and metabolism-related 
genes uniquely associated with Rlow.  Targeting those components of attenuated vaccine strains 
Mg7 and GT5 that have stimulated a host response lacking immune-related pathogenesis while 
promoting the successful connection between the innate and adaptive responses, will result in a 
safe vaccine capable of providing long-term protection from virulent strains of M. gallisepticum. 
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Materials and Methods  
  
  
Animals 
 Four-week-old female specific-pathogen-free White Leghorn chickens (SPAFAS, North 
Franklin, CT, USA) were divided randomly into four groups of 10, placed in HEPA-filtered 
avian isolators, and allowed to acclimate for one week. Non-medicated feed and water were 
provided ad libitum throughout the experiment. All components of the study were performed in 
accordance with approved UConn IACUC protocol number A13-001. 
 
Chicken Infection 
 Stocks of M. gallisepticum strain Rlow (passage 17) were grown in Hayflick’s complete 
medium overnight at 37°C until mid-log phase was reached as indicated by a color shift from red 
to orange. Vaccine strains Mg7 (passage 6) and GT5 (passage 5) were grown in Hayflick’s 
complete medium with gentamicin selection (150 µg/ml) as previously described (20). Bacterial 
concentrations were determined by the OD620 and 10-fold serial dilutions were conducted to 
confirm viable color-changing-unit titers. Bacteria were pelleted by centrifugation at 10,000 x g 
for 10 minutes and resuspended at 5 x 108 CFU/ml in Hayflick’s complete medium. Chickens 
were infected by pipetting 1 x 108 CFU/200 µl of Rlow, Mg7, or GT5 (‘infection groups’), or 
200 µl of Hayflick’s medium alone (‘control group’) into the tracheal lumen as previously 
described (52). 
 
RNA Extraction 
 Fifteen infected (5 per ‘infection group’) and five ‘control’ chickens were humanely 
sacrificed at 24 and 48 hours (‘days 1 and 2’) post-infection. Tracheas were excised and total 
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RNA was immediately stabilized by pipetting 1 mL TRIzol reagent four times through the lumen 
of each individual trachea (52) to minimize the changes in gene expression that may occur 
during the time between specimen collection and RNA purification (Invitrogen, Carlsbad, CA, 
USA), and stored at -80º C.  Total RNA was then purified using the Zymo-Direct-zol RNA 
Miniprep Kit according to manufacturer’s instructions (Zymo Research Corperation, Irvine, CA, 
USA). 
 
Illumina Sequencing 
 cDNA libraries were created from RNA isolated from each individual chicken on days 1 
and 2 post-infection using the Illumina TruSeq Stranded mRNA Library Preparation Kit 
(Illumina Inc., San Diego, CA, USA) according to the Illumina TruSeq RNA Sample Preparation 
v2 (HT) protocol. Briefly, PolyA selection was performed using RNA purification beads on 0.1-
4 µg of total RNA per sample to obtain mRNA. 10-400ng of purified mRNA was fragmented 
and used to synthesize first-strand cDNA using reverse transcriptase and random hexamer 
primers.  Second-strand cDNA synthesis was performed using dNTPs including dUTP, DNA 
polymerase, and RNase. End repair was performed by adding dATP to all free 3’ ends and 
adaptor ligation added unique index sequences to the fragments.  The products were then 
amplified by PCR and purified. 
 The cDNA libraries were quantified using the Qubit 2.0 fluorometer (Invitrogen) and 
assessed for correct fragment size (~260bp) using the Agilent TapeStation 2200 (Agilent 
Technologies). Libraries were normalized to 2nM, pooled, denatured and sequenced on the 
NextSeq500 Sequencing platform (Illumina Inc.) using a 75bp paired-end approach targeting 
approximately 10 million reads per sample.  
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RNA-Seq Analysis 
Fastq data from individual birds were mapped using the TopHat package (version 2.0.1) 
utilizing the Bowtie2 engine (version 2.2.5) to align reads to the Gallus gallus reference genome 
(WASHUC2) producing BAM alignment files (53,11).  BAM files for each day were processed 
as experimental condition groups with Cufflinks (version 2.2.1) as previously discussed (10). 
Within-condition normalization of data using Cuffdiff was achieved by calculating the fragments 
per kilobase of exon per million fragments mapped (FPKM) for each gene. The generated p-
value was then used to determine the significance of the differential expression based on the 
Benjamini-Hochberg correction with a false discovery rate (FDR) of <5% to generate the q-
value.  Between-condition differences in expression values were considered significant when q ≤ 
0.05, thus addressing within-condition variation for all biological replicates on each day. Fold 
change was determined from the log2 transformation of the ratio of FPKM between conditions 
(53, 54). For this study, all references to differentially expressed genes (DEGs) implies statistical 
significance. 
 
Pathway Analysis 
Identification of biological pathways that significant DEGs were involved in, was 
performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
version 6.7 (55). Pathways containing ≥ 2 significant DEGs were categorized and displayed. 
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Functional Gene Ontology 
 DEGs with a log2 fold change ≥ 2.00, as identified by Cuffdiff, were analyzed to identify 
enriched biological processes based on Gene Ontology (GO).  This was performed using 
ClueGO v2.3.3, a plugin of the software platform Cytoscape v3.5.1 (56).  ‘GO term fusion’ was 
applied to reduce redundancy by comparing ‘parent-child’ relation sharing similar genes and 
displaying the more representative ‘parent’ or ‘child’ term (56). Processes that had a p-value ≤ 
.05 for each time point were considered significant and displayed.  
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FIG 1 The number of DEGs determined by comparing each infection group (Rlow, Mg 7 and 
GT5) to the respective control group as identified by Cuffdiff. (a) The overall number of DEGs 
identified in each group on days 1 and 2 post-infection. (b) The number of DEGs with increased 
or decreased expression. (c) Venn diagram displaying the DEGs per infection group. The number 
of unique and common DEGs are displayed. 
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FIG 2 Pathway analysis. Pathways containing ≥ 2 DEGs were categorized based on function 
using DAVID Bioinformatics software. (a & c) The number of identified pathways per category 
is indicated for each infected group on day 1 (a) and day 2 (c) post-infection. (b & d) The 
number of DEGs per pathway category is indicated for each infected group on day 1 (b) and day 
2 (d) post-infection. 
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FIG 3 Immune Pathways. DEGs involved in these pathways are indicated for each infection 
group; red stars (Rlow), blue stars (Mg 7), and yellow stars (GT5) as identified by DAVID 
Bioinformatics software. Green shading represents the completeness of the pathway identified 
within the Gallus gallus genome. 
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Day 1 
 
 
Day 2 
 
FIG 4 Toll-like receptors. TLRs identified by RNA-Seq analysis are displayed. Differential 
expression is expressed as log2 fold change. Individual bars indicating Rlow, Mg 7, and GT5 
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represent differential expression seen between each infection group and the control group. 
Significant differential expression of TLRs between infected and control birds are indicated with 
an (*) above its respected bar. Significant differential expression compared directly between 
infection groups (Rlow vs. Mg 7) and (Rlow vs. GT5) is indicated across the top of the bars with      
*   .  Differential expression is considered significant at q ≤ 0.05. 
 
 
 
 
 
TABLE 1 Top 30 common DEGs as determined by Cuffdiff and ranked based on the log2 fold 
change values in the Rlow infection group. 
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FIG S1 Functional Gene Ontology. Significant DEGs with a log2 fold change ≥ 2.00 were 
analyzed for enriched biological processes using the ClueGO application for Cytoscape. ‘GO 
term fusion’ was applied to reduce redundancy by comparing ‘parent-child’ relation sharing 
similar genes and displaying the more representative ‘parent’ or ‘child’ term.  Bars represent the 
percentage of associated genes assigned to a unique GO term with the absolute number of 
associated genes located at the end of the bars. The color of the bars indicates functionally 
related groups based on the similarity of associated genes. Significance of enriched biological 
processes are as indicated (* = p £ 0.05, ** = p £ 0.001). 
 
 
FIG S2 Top 30 DEGs identified in the GT5 infection group as determined by Cuffdiff. Genes 
are ranked based on the log2 fold change. Fold change is considered significant at a q-value of 
≤0.05. 
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FIG S3 Top 30 DEGs common only to the Rlow and Mg 7 infection groups as determined by 
Cuffdiff. Genes are ranked based on the log2 fold change of the Rlow infection group.  
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FIG S4 Top 30 DEGs unique to the Rlow infection group as determined by Cuffdiff. Genes are 
ranked based on the log2 fold change values. 
 
 
FIG S5 Log2 fold change of CASP1 and P2RX7 expression in each infection group as 
determined by Cuffdiff. Fold change is considered significant at a q-value of ≤0.05. 
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CHAPTER 4: 
 
Conclusions and Future Directions 
 
Conclusions  
 
The overarching goal of this research was to evaluate the host tracheal response using an 
unbiased, global approach.  To do this, we sampled host cell RNA by pipetting TRIzol through 
the tracheal luman, enabling the recovery of RNA from cells that were in the closest proximity to 
M. gallisepticum.  Collectively, these transcriptomic studies have expanded our understanding of 
the magnitude of the chicken tracheal response to virulent M. gallisepticum strain Rlow over a 7-
day time course, and the comparatively dampened host response elicited by laboratory attenuated 
vaccine strains Mg 7 and GT5 during early infection.  Furthermore, these data enabled the 
functional analysis of biologically relevant pathways and how their varied involvement may 
contribute to the maladaptive or beneficial host response to virulent and attenuated strains of M. 
gallisepticum, thereby providing critical information with regards to pathways and gene products 
to either be included or excluded in the response to future vaccine preparations. 
 In the time course analysis of the tracheal host response to virulent Rlow, we observed a 
significant pro-inflammatory response involving several immune related pathways involving 
many DEGs that peaked at day 3, and trended towards baseline expression values by day 7.  The 
peak of infection, as indicated by the greatest number and fold change seen in DEGs, gross 
pathology, and bacterial recovery, was approximately 10-12 days earlier than the peak of 
infection and subsequent lesion scores that have been observed in other studies (1–3).  However, 
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it is important to note that previous studies inoculated chickens twice, whereas our study used a 
single inoculation.  
 The significant pro-inflammatory response was not only reaffirmed through 
transcriptional analysis, it identified additional genes involved in this response that were not 
previously appreciated in the host response to M. gallisepticum. Previous studies have shown the 
importance of predominant TLR-2 signaling and the subsequent production of pro-inflammatory 
cytokines in response to Rlow infection, while other TLRs including TLR-15 and TLR-4 were 
observed, they were expressed at a far lesser degree than TLR-2 (4, 5).  Our data further support 
the importance of TLR-2, however the increased expression of TLR-15 and TLR-4 were 
considerably greater than TLR-2.  TLR-15 was recently shown to be activated in the presence of 
M. synoviae lipoproteins (6), and therefore, it is not surprising to find increased expression of 
this TLR given the interaction between M. gallisepticum lipoproteins and host tracheal mucosa. 
It is however, important to consider the role that TLR-15 may play in the pro-inflammatory 
response.  TLR-4 expression has also been associated with other Mycoplasmas including M. 
pneumoniae (7), M. arthritidis (8), and M. hyorhinis (9), though the direct role it may play in the 
pathogenesis of disease remains uncertain.  The potential role of TLR-4 as a receptor for DAMPs 
(10–12) suggests a possible scenario in which the damage to host cells caused by M. 
gallisepticum results in the activation of TLR-4.  The increased expression of TLR-4 may 
indicate another pathwy capable of resulting in pro-inflammatory cytokines such as IL-1β, IL-6, 
IL-8 and IL-12.  Furthermore, expression of TLR-15 and TLR-4 in Mg 7 and GT5 infected 
chickens were significantly less than Rlow infected chickens, suggesting an association of the host 
response to the virulence status of the bacteria.  While the changes seen in TLR expression may 
in part be due to changes in the inflammatory cells infiltrating the lamina propria, these findings 
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have identified additional potential mediators of the host inflammatory response that warrant 
further study. 
 In addition to TLRs, there were numerous cytokine and chemokine receptors that showed 
significant differential expression as a result of Rlow infection.  In comparison, Mg7 infection 
resulted in 60% fewer differentially expressed receptors on day 1 post-infection and 24% on day 
2, and GT5 infection only resulted in three differentially expressed receptors.  This suggests that 
Rlow infection may increase host cell sensitivity to signaling molecules present on mycoplasma, 
DAMPs, endogenous gram-negative bacteria, and host factors such as chemokines and 
cytokines.  With the increased expression of cytokines and chemokines and probable cell stress 
present upon Rlow infection, the increased expression of host cell receptors may contribute to the 
exaggerated and dysregulated host response to virulent M. gallisepticum.  
 The extent of the host’s metabolic activity upon M. gallisepticum Rlow infection was also 
striking; affecting the greatest number of genes on days 1, 2, and 3 post infection.  The number 
of metabolic genes activated in Mg 7 was considerably less, while GT5 infection activated the 
least number of metabolic genes. This finding is likely indicative of reduced cellular stress 
during infection with attenuated strains, and correlates with the levels of TLR-4 expression seen 
in each infection group and the likely presence of DAMPs.  It is also possible that the increased 
cell stress and metabolic activity seen during Rlow infection yields greater levels of extracellular 
ATP which subsequently binds purinergic receptors, and potentially activating the Nlrp-3 
inflammasome.  This was reflected in the gene expression profiles as the P2X7 purinergic 
receptor for extracellular ATP, and CASP1, a regulator of the Nlrp-3 inflammasome, were 
significantly expressed in both Rlow and Mg 7 infected chickens, with greater values observed in 
the Rlow infected chickens.  Tthe end-product of inflammasome activation, IL-1β,  was 
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significantly expressed in each infection group, with the greatest levels were seen in Rlow 
infected chickens.  By day 2, expression was no longer significant in the GT5 infected chickens.  
As these genes are components of the NOD-like receptor pathway, these data suggest that this 
pathway may play an important role in pathogenesis during infection with virulent mycoplasma. 
This offers insight as an immune related pathway to avoid activating by using strains with 
limited cytadhesion capabilities to limit the contact with host cells when designing future 
vaccines. 
Comparison of the host response to virulent of Rlow to the attenuated immune responses 
elicited by Mg 7 (13, 14) and GT5 (1, 14, 15), has identified host genes that may serve as safe 
and effective targets for future vaccines.  These potential gene targets include those that are 
uniquely expressed in Mg 7, and genes expressed in either Rlow and/or Mg 7 that are common 
with GT5 (Fig. 1c, p. 139).  It may be necessary to include some genes whose expression is 
induced in Rlow and Mg 7, however, those that are unique to Rlow likely contribute to the 
immunopathology observed during Rlow infection.  For example, as seen in the cytokine-cytokine 
receptor pathway, there are several host cell receptors significantly expressed only during 
infection with Rlow, several others that are expressed during Rlow and Mg 7 infection, while GT5 
infection only resulted in a select few. This suggests that ligands of the receptors activated during 
Rlow infection should be avoided; thereby decreasing the sensitization of the host cell and 
reducing the downstream products resulting from receptor activation.  In contrast, while 
activated by cytokines, expression of genes within the Jak-STAT pathway were similar between 
the three strains, suggesting that this pathway does not contribute to a maladaptive host response. 
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Future Directions 
 
 A caveat to the studies presented here, is the uncertainty as to which cells the mRNA 
transcripts were produced from. Therefore, some of the changes seen in expression values may 
well be in part due to the changing abundance of immune cells.  Nonetheless, this data provides 
us with important insights into the host’s overall response to infection with M. gallisepticum.  
Although beyond the scope of this project, future studies should focus on the identification of the 
specific host cells which are responsible for the increase in transcripts thought to be important in 
the host immune response.  This could be accomplished by in situ hybridization, laser capture 
microdissection, or single-cell sequencing analyses.  This would further elucidate the host 
response and the critical roles that some cells likely play in either immunopathology or a 
protective immune response.   
 It was recently shown that interaction of M. bovis with neutrophils prevents the release 
NETs, however, it also induces increased elastase production in neutrophils which degrades the 
ECM (16).  Early infection with M. gallisepticum results in the infiltration of heterophils into the 
lamina propria which are thought to play a significant role in host immune response (17, 3).  It 
would be of interest to determine whether interaction of M. gallisepticum with chicken 
heterophils also prevents the release of HETs and whether elastase production is increased (18).  
While elastase is intended to aid in the killing of pathogens by degrading the membrane, release 
of elastase and the subsequent degradation of the host ECM may only contribute to tissue 
damage during acute inflammation. Additionally, the degradation of the ECM may play a role in 
the pathogenesis of disease as M. gallisepticum contains surface molecules OsmC and PlpA that 
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bind ECM components heparin and fibronectin respectively, and may therefore contribute to an 
environmental niche aiding in the chronicity of M. gallisepticum (19, 20).   
 Transcriptional analysis has provided a global assessment of the host response; however, 
transcription does not necessarily mean translation. To better understand which gene transcripts 
are actually being translated and therefore affecting the host response, it would be beneficial to 
utilize ribosomal profiling to then perform transcriptional analysis only on those transcripts that 
were undergoing active translation (21).  
 Creation of the Mg 7 vaccine strain through transposon mutagenesis of the lpd gene of 
Rlow did not affect its capability of cytadhesion, however, GT5 cytadhesion capabilities remained 
equivalent to that of Rhigh at approximately 24%. By two weeks post infection, GT5 is not 
recovered from infected chickens (1, 14, 15), and Mg 7 was only recovered in approximately 
12% of infected chickens.  While this may be partly due to clearance of the organism through 
host mechanisms and/or the immune response, it is likely that the inadequate ATP production of 
Mg7 and limited cytadhesion of GT5 play roles in this clearance.  While the growth curve of 
Mg7 has shown to be comparable to that of Rlow over a 54-hour growth period, it is uncertain 
how long Mg7 stays in contact with the tracheal mucosa (13). Therefore, transcriptional analysis 
of the F strain that is capable of providing protection from virulent strains and known to persist 
in the host over a long period of time (22), may provide useful insights regarding a host response 
that develops during constant contact with the organism.  Additionally, because the host response 
to Mg 7 more closely resembled the host response to Rlow by day 2 post-infection, it may be 
advantageous to understand the changes that occur in the host response to Mg 7 as the course of 
infection continues. This would enable comparisons to be made at the height of infection/peak 
host response, and may assist in understanding the differences between Rlow and Mg 7 in the 
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transition from the innate to adaptive host immune response to virulent and attenuated strains.  
This would be important especially given the significance that the Th1 and Th2 balance play in 
mycoplasma pathogenesis and the cytokines and chemokines that may be involved in this 
process. 
 In conjunction with these studies, Dr. Katherine Pflaum of our lab, sequenced M. 
gallisepticum RNA obtained from the tracheas of the same infected chickens to assess the 
changes in vlhA expression (23).  This was a comprehensive host/pathogen analysis over the 
course of early infection.  Interestingly, changes in vlhA gene expression were seen as early as 1-
2 days post-infection. And while these changes are occurring before the development of specific 
antibodies (1), it is likely that interaction between the host and pathogen contribute to vlhA 
expression changes.  Further understanding of the changes in vlhA expression and their 
interaction with host cell receptors such as TLRs 1, 2, 6, 15 and NOD-like receptors may identify 
important mechanisms in cellular activation and signaling that occur in the presence of M. 
gallisepticum. 
 The global transcriptional analysis of the host response to virulent M. gallisepticum Rlow 
and the differences seen in the response to attenuated vaccine strains Mg 7 and GT5, has 
provided further understanding of how complex the response to this pathogen is.  The studies 
presented here emphasized significant changes in genes with metabolic and immune functions 
during M. gallisepticum infection, and have implied the importance of host cell receptors and the 
production of chemokines and cytokines that likely ensues.  While many genes active in the host 
response to Rlow are likely important in the activation of the adaptive immune response, the 
magnitude of expression should resemble that seen in response to Mg7.  Overall, future vaccine 
development should focus on targeting those genes that were differentially expressed in both 
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virulent Rlow and attenuated vaccine strains Mg7 amd GT5.  Specifically, limiting the expression 
of host cell receptors and proinflammatory cytokines while ensuring the production of 
chemokines and cytokines including, but not limited to IL-8, IL-12B, CCL4, and IFN-γ, will 
enable the innate response to activate protective adaptive immunity. These data, coupled with 
future analyses aimed at identifying the specific cells, gene products, and their direct 
implications on the host response will aid in the development of future therapeutics and vaccines. 
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